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INTRODUCTION
1	 	For	the	purposes	of	this	report,	DR-TB	is	defined	as	resistance	to	at	least	isoniazid	and	rifampicin,	to	include	MDR-TB	and	XDR-TB.
Tuberculosis (TB) is the leading infectious disease killer 
globally, and in 2016 it claimed the lives of 1.7 million 
people. This deadly disease caused by Mycobacterium 
tuberculosis (MTB) is transmitted through the air from 
person to person, and occurs in the United States 
and around the world. TB is curable, but inappropriate 
treatment can lead to drug-resistant TB (DR-TB).1 
Multidrug-resistant TB (MDR-TB) and extensively 
drug-resistant TB (XDR-TB) are both increasing global 
health security threats. An outbreak of MDR-TB would 
have serious consequences for individuals, because of 
the long, difficult and toxic treatment regimen required. 
Health systems and economies will also suffer, because 
of the very high cost of treatment, as well as the 
burden DR-TB places on providers, institutions and 
health systems.
In December 2015, the U.S. Government released 
a plan to address the growing TB crisis domestically 
and internationally and to advance research on this 
critical public health issue. The National Action Plan for 
Combating Multidrug-Resistant Tuberculosis (National 
Action Plan) is a five-year plan that builds on, and 
contributes to, the U.S. Government’s domestic and 
global TB strategies, as well as the END TB Strategy, of 
the World Health Organization (WHO) and the Stop 
TB Partnership’s Global Plan. 
The goals of the National Action Plan are to 
accomplish the following:
1.  Strengthen domestic capacity to combat MDR-TB;
2.  Improve international capacity and collaboration to 
combat MDR-TB; and
3.  Accelerate basic and applied research and 
development to combat MDR-TB.
From 2000 to 2016, global efforts to ensure TB 
diagnosis, treatment and care saved an estimated 53 
million lives. The U.S. Government is a leader in these 
efforts, working through its Departments and Agencies, 
to support implementation of high-quality services. The 
National Action Plan builds on these efforts to support 
the appropriate treatment of more than 16 million TB 
patients, ensure that 90 percent of them are cured, and 
prevent further development of MDR-TB. In addition 
to increased efforts to diagnose, cure and prevent 
MDR-TB, the National Action Plan proposes to 
increase the number of MDR-TB treatment initiatives 
in countries with the highest MDR-TB burden. 
The National Action Plan is intended to promote 
greater coordination of U.S. Government resources—
including domestic, bilateral and multilateral funding—
to reduce the domestic and global risk of MDR-TB; 
increase the American public’s awareness of the threats 
posed by the disease; and serve as a call to action to 
encourage bilateral and multilateral donors, the private 
sector and affected countries to increase investments 
in this critical area of worldwide concern. Additional 
investments in research and development will continue 
to contribute to improved treatment outcomes for 
individuals with MDR-TB through the discovery of 
new tools that are easy to implement in existing health 
systems; the increased availability of rapid diagnosis; 
the better use of new TB drugs; an enhanced drug-
development pipeline; effective vaccines and other 
preventative interventions; and improved disease 
surveillance. These actions help prevent the emergence 
of further resistance to TB drugs, and significantly 
reduce the global spread of MDR-TB.
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GOAL 1: STRENGTHEN DOMESTIC CAPACITY TO 
COMBAT MULTIDRUG- RESISTANT TUBERCULOSIS
2  HL7 refers to the seventh level of the International Organization for Standardization (ISO) communications model for Open Systems 
Interconnection. 
Following an increase that coincided with both the 
onset of the HIV epidemic and decreasing support and 
resources for TB control and prevention programs, the 
incidence of TB in the United States steadily declined 
from 1993 through 2014. After substantial progress 
during the past two decades, the rate of TB cases in 
the United States each year has now levelled off and 
remains well above the elimination threshold of less than 
one case per million persons. Although rates of MDR-
TB have declined since 1993, annually, approximately 
1 percent of U.S. TB cases are MDR-TB; the majority 
(greater than 90 percent) occur among non U.S.-
born persons. DR-TB cases complicate treatment and 
prevention efforts and are extremely expensive for 
state and local TB programs to manage. TB programs 
ensure continuity of care so that drug-resistance does 
not develop among persons with lack of access to 
consistent healthcare services. This includes provision of 
wraparound services such as patient education. The TB 
program in the state health department is responsible 
for coordination and oversight of activities to ensure 
that objectives related to TB prevention and control 
are achieved. The U.S. Centers for Disease Control 
and Prevention (CDC), within the U.S. Department of 
Health and Human Services (HHS), provides funding 
and technical assistance to help TB programs address 
the burden of MDR-TB in each state. A single case of 
MDR-TB costs 10 times more to treat (approximately 
$160,000) compared to a drug-sensitive case (DS-
TB) (approximately $18,000); thus support for 
better treatment options, rapid diagnosis and expert 
management are essential to prevent and control MDR-
TB in the United States.
OBJECTIVE 1.1: UPGRADE TB 
SURVEILLANCE TO ENSURE COMPLETE 
AND ACCURATE DETECTION OF 
DRUG-RESISTANT TB 
CDC is upgrading surveillance systems for tracking 
DR-TB cases in the United States to capture molecular 
test results and more detailed clinical information 
about each case, which will enable better tracking of 
disease burdens, targeting of resources, and linkages 
to care and contact investigations. CDC is working 
with state TB programs to identify common language 
and protocols for reporting drug-resistance to anti-TB 
drugs. A molecular drug susceptibility testing reporting 
(MDSTR) form has been successfully developed and 
tested within the National TB Surveillance System to 
provide standardization. Implementation of electronic 
links between clinical laboratories and TB surveillance 
programs at the federal, State, and local levels are 
also underway; CDC is in the beginning stages of 
developing and implementing HL7 standardized coding 
for Electronic Laboratory Reporting (ELR) into state 
surveillance systems as well as standardized coding for 
electronic transmission from state surveillance systems 
and CDC labs into the National TB Surveillance 
System Case Reporting MDSTR data collection 
system.2
OBJECTIVE 1.2: STRENGTHEN STATE 
AND LOCAL CAPACITY TO PREVENT 
TRANSMISSION OF DRUG-RESISTANT TB
CDC has also expanded data collection for drug 
susceptibility testing results to be included in the new 
version of Report of Verified Case of Tuberculosis 
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(RVCT). This will enable epidemiologists to identify 
related cases of DR-TB and DS-TB that have been 
recently transmitted to facilitate targeted interventions 
to prevent additional transmission. State and local TB 
programs will also be able to use this improved data to 
more effectively define their burden of DR-TB.
OBJECTIVE 1.3: ENSURE THAT PATIENTS 
WITH DRUG-RESISTANT TB RECEIVE 
TREATMENT UNTIL CURED
Completion of treatment for those with MDR-TB is 
challenging on many levels. The activities supported 
by CDC to meet this objective encompass a broad 
range of interventions implemented by state and 
local health departments with funding and assistance 
from CDC headquarters. Electronic directly observed 
therapy (eDOT) is the use of electronic technologies 
to remotely monitor TB patients ingesting their 
medication, either in real-time or recorded. Because 
eDOT is an alternative method of delivering 
medication in which a patient is remotely observed 
(e.g., over a smartphone), it may improve adherence 
and be more cost-efficient than traditional in-person 
directly observed therapy (DOT). The benefits to 
having an eDOT program include, convenience for 
patients and staff, in addition to reduced staff travel 
cost and time. A form of eDOT was used successfully 
in 2016 by the Puerto Rico Department of Health 
(PRDH). Due to staffing shortages PRDH TB field 
personnel were not available to administer daily 
DOT. Use of video DOT saved PRDH approximately 
240 hours in DOT-related activities, equivalent to 25 
percent of the workload for a full-time epidemiology 
technician/case manager over six months of treatment. 
A randomized control trial is now underway to assess 
the efficacy of eDOT for treating TB disease as well 
as an economic evaluation. Results will help inform 
the needs that MDR-TB patients require in order to 
successfully complete their long, and often debilitating, 
treatment regimen. CDC, in collaboration with the 
HHS Supply Service Center, is successfully managing 
and maintaining a stockpile of TB drugs to have on 
hand in the event of manufacturer shortages that 
could result in interruption of treatment. The stockpile 
is composed of a small supply of drugs that would be 
necessary to protect TB patients and communities in 
the event of a time-limited manufacturing shortage. 
CDC has also developed a U.S.-Mexico binational case 
definition for the national TB surveillance system that 
can be measured using current performance indicators, 
including Completion of Therapy. This new definition 
will be published in 2018.
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GOAL 2: IMPROVE INTERNATIONAL CAPACITY  
AND COLLABORATION TO COMBAT  
MULTIDRUG-RESISTANT TUBERCULOSIS
3  National Action Pllan countries: Burma, the People’s Republic of China, India, Indonesia, Kazakhstan, Nigeria, Pakistan, the Philippines, South Africa 
and Ukraine.
4  Bedaquiline (BDQ) is a recently developed anti-TB medication which is prescribed for patients with advanced forms of MDR-TB and XDR-
TB. Treatment success rates using BDQ-inclusive treatment regimens show results greater than 80 percent vs. 25 percent in non-BDQ-inclusive 
treatment regimens. 
5  STR is a novel approach to DR-TB treatment that utilizes treatment regimens designed for up to 11 months of use instead of the conventional 
standard of care, which can last up to 24 months. 
As the lead U.S. Government agency for global 
TB-control efforts, the U.S. Agency for International 
Development (USAID) works with CDC and other 
Departments and Agencies to reach every person 
with TB, cure those in need of treatment and prevent 
new TB infections. Progress towards detection and 
treatment of patients with DR-TB remains a challenge, 
primarily because of health-system constraints related 
to diagnostic and care services. In 2016, the most 
recent year for which complete data are available, 
there were an estimated 600,000 new cases of DR-TB 
globally. Because of the timing of the collection and 
data analysis and in the interest of providing the most 
recent data, the National Action Plan Annual Report 
presents preliminary national TB program data. 
This Year Two report provides an update on the 
final 2016 data as well as the preliminary 2017 data. 
Finalized 2016 data for the first year of the National 
Action Plan’s implementation appear below:
Globally: 
 § 153,119 DR-TB cases detected, which reflects slightly 
more than 25 percent of the estimated total DR-TB 
cases; and 
 § 129,689 DR-TB patients enrolled on treatment, 
which reflects almost 22 percent of the estimated 
total DR-TB cases.
In National Action Plan countries3: 
 § 101,702 DR-TB cases detected, which reflects 66 
percent of the total DR-TB cases detected globally; 
and
 § 81,876 DR-TB patients enrolled on treatment, which 
reflects 63 percent of the total DR-TB patients 
enrolled globally: 
 -4,277 DR-TB patients enrolled on a regimen 
that contains bedaquline (BDQ);4 the majority of 
these patients were treated for XDR-TB; and 
 -272 DR-TB patients enrolled on a shorter 
treatment regimen (STR).5
Figure 1: DR-TB Detection and 
Treatment, Year One
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Source:  National TB Programs and the 2017 WHO Global TB Report
The data reported in this Year Two Report for 2017 
should be considered preliminary, as they are based 
on nine months of validated data, and project the 
outcomes for the full 12 months of 2017. The Year 
Three report will reflect the finalized 2017 data, as well 
as preliminary 2018 data. Compared to Year One 
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results, the National Action Plan countries saw a slight 
increase in the number of DR-TB cases detected 
and enrolled on treatment in Year Two. However, the 
number of XDR-TB patients who initiated the most-
appropriate treatment (with new TB medications), is 
projected to increase significantly to more than 8,020, 
an estimated 88 percent increase over Year One. 
Estimates for the implementation of the Year Two 
National Action Plan, implementation based on 
preliminary 2017 data and our projections are as 
follows:
 § 104,500 DR-TB cases detected; and
 § 84,500 DR-TB patients enrolled on treatment; 
 -8,020 DR-TB patients enrolled on a regimen that 
contains BDQ; and 
 -5,600 patients enrolled on STR. 
While no additional funds were provided for the 
implementation of the National Action Plan in Year 
Two, USAID and CDC prioritized resources to 
implement the MDR-TB activities in the National 
Action Plan. The table following is an estimate of the 
funding made available for these activities using USAID 
and CDC programmatic data. 
Table 1: Estimated U.S. Government 
Funding for Implementation of Goal 2  
National Action Plan Country 
Investments, Year Two 
U.S. Government 
Department or Agency
Funding 
Total
USAID* $24,034,000
CDC $3,523,000
*Includes $1.2 million USAID funding provided to CDC for 
implementation of the National Action Plan.
Nineteen-year-old Siba Senapati was 
diagnosed with pulmonary drug-
resistant TB in October 2017.  
Photo by Muktai Panchal
CONTROL OF DR-TB BY THE PRIVATE AND 
PUBLIC SECTORS IN MUMBAI, INDIA
While most DR-TB patients in India present for evaluation and 
diagnosis in the private sector, quality DR-TB care is primarily available 
only in the public sector. USAID and CDC jointly support linking the 
private and public health sectors to improve access for patients to 
DR-TB care. DR-TB patients in private health settings first receive pre-
treatment evaluation and testing, and then a referral in 23 additional 
cities for fast-tracked treatment initiation at DR-TB centers in the public 
sector. Treatment coordinators accompany the patients throughout 
the transfer process and ensure patient-centered support. This unique 
patient-support system has boosted the trust and confidence in the 
public-sector DR-TB care, and ensures more private-sector patients 
receive the appropriate treatment. This model is now being scaled-up 
across the country through funding from the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (Global Fund) support. 
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OBJECTIVE 2.1: IMPROVE ACCESS TO 
HIGH-QUALITY, PATIENT-CENTERED 
DIAGNOSTIC AND TREATMENT 
SERVICES 
In 2017, National Action Plan countries expanded 
services and activities initiated during the first year. TB 
detection expanded through the scale-up of diagnostic 
tools, which resulted in more people screened and 
tested. India underwent comprehensive international 
reviews of its diagnostic networks. Recommendations 
from these reviews will further strengthen and 
improve TB-detection capacity in the future. 
Significant progress also occurred in scaling up the use 
of appropriate regimens for people diagnosed with 
XDR-TB, which is resistant to even more drugs than 
MDR-TB. Clinicians are now treating both XDR-TB 
and MDR-TB with BDQ; the number of patients who 
have access to this new drug has doubled because of 
the USAID- Johnson and Johnson (JNJ) Bedaquiline 
Donation Program. Rapid scale-up of STR, newly 
recommended by the WHO, was also observed, 
with a projected 5,600 patients in 2017, an estimated 
2000-percent increase over 2016. 
Sub-objective 2.1.1: Strengthen the capacity of 
national TB laboratory networks to diagnose TB 
and MDR-TB
In 2017, USAID, with assistance from the Government 
of India, led a comprehensive review of its national TB 
diagnostic networks, and revision of its National TB 
Strategic Plan. In addition, USAID, CDC and the Global 
Fund supported Nigeria to conduct a comprehensive 
assessment of its national sample-transportation 
systems to identify network modifications that could 
reduce the time and distance between patients 
and TB diagnostic services. Lastly, USAID and CDC 
worked to improve the quality of TB laboratory 
services by assisting multiple TB-reference laboratories 
in National Action Plan countries, including China 
A NTRL medical technologist demonstrates her 
skill in preparing a TB culture required by ISO 
15189. Photo by T. Bernas/PBSP.
NTRL AWARDED ACCREDITATION BY  
THE INTERNATIONAL ORGANIZATION 
FOR STANDARDIZATION (ISO)
USAID provides vital technical support to both achieve National 
Action Plan milestones and to improve and sustain national TB 
diagnostic services. In late 2017, the Philippines Department of 
Health’s NTRL received ISO 15189 accreditation, an international 
standard that specifies the quality-management requirements 
for medical laboratories, with technical assistance from USAID. 
USAID assisted in documenting technical and management 
Standard Operating Procedures, including NTRL’s Quality Manual. 
Issued by the Accreditation Bureau of the Philippine Department 
of Trade and Industry, the accreditation places a quality seal on 
all laboratory procedures provided by the NTRL and guarantees 
end-users of the safety, reliability and quality of its procedures.
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and the Philippines, to work towards international 
accreditation (see box below), and trained National 
TB Reference Laboratory (NTRL) staff in India. All 10 
National Action Plan countries should have National 
Laboratory Strategic Plans (NLSPs) developed and 
approved by the end of Year Three. These plans will 
incorporate new diagnostic technologies, WHO-
approved rapid TB-detection tools, and evidence-based 
strategies to strengthen detection of TB and DR-TB 
cases. In addition to improving patients’ access to 
TB and DR-TB laboratories for enhanced diagnosis 
and treatment, USAID and CDC are working with 
Ministries of Health, National TB Programs (NTPs) and 
local partners across National Action Plan countries 
to optimize the use of TB testing services and improve 
access to testing throughout all levels of healthcare.6
Sub-objective 2.1.2: Expand and strengthen 
national MDR-TB care and treatment capacity to 
optimize the use of current and novel regimens
Novel drugs, such as BDQ and delamanid (DLM), 
have recently been introduced in countries with 
high burdens of DR-TB. Introduction of new drugs 
and STRs to manage DR-TB offers patients and 
healthcare providers hope for improved treatment 
outcomes. These drugs are frequently the only chance 
to cure XDR-TB patients. During the first year of the 
implementation of the National Action Plan, USAID 
initiated work in seven countries to bring these new 
lifesaving drugs and regimens rapidly to patients. In 
2017, assistance provided by USAID resulted in a 
projected 8,020 DR-TB patients in BDQ-containing 
regimens, and a projected 200 patients enrolling in 
DLM-containing regimens, a significant increase over 
the preceding year. 
In 2017, the Bedaquiline Donation Program led to a 
five-fold increase in global access to BDQ in more than 
60 countries. As a result, approximately 8,020 patients 
are projected to receive treatment, free of cost, in 
National Action Plan countries. 
6  Country national TB laboratory systems consist of a National Reference Laboratory, regional/Provincial laboratories, District-level laboratories and 
sub-District laboratories.
Figure 2: BDQ and STR Progress in 
National Action Plan Countries
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Source:  National TB Programs and the 2017 WHO Global TB Report
Sub-objective 2.1.3: Strengthen TB/MDR-TB 
surveillance and monitoring systems
Monitoring and tracking TB and DR-TB is a critical 
component in the management of TB, because it 
allows the identification of trends, challenges and 
successes, and technical and programmatic areas that 
require additional attention. In 2017, USAID supported 
the WHO’s TB disease surveillance and progress 
monitoring. In October 2017, the WHO updated its 
Global TB Report and the global TB public database, 
which contain comprehensive global and national TB 
data used by partners involved in national and global 
efforts to eliminate TB.
In National Action Plan countries, USAID and CDC 
work to strengthen TB surveillance systems, support 
the scale-up of electronic TB databases, and conduct 
drug-resistance surveys. In China, CDC performed a 
pilot TB-inventory study, the results of which led the 
National Center for TB Control to realize the need 
for routine record linkages between the results of the 
national TB-surveillance system, health facilities and 
insurance systems. In India, USAID funded the first-ever 
drug-resistance survey to understand drug-resistance 
levels and patterns, and inform treatment policies. 
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The U.S. Government and the Global Fund to 
Fight AIDS, Tuberculosis and Malaria
The United States was the founding donor to the 
Global Fund in 2001 and is still the largest donor to 
the organization. The U.S. Government’s TB lead serves 
at the Global Fund Board meeting as part of the U.S. 
Delegation. Seventeen years of collaboration means 
U.S. bilateral TB programs and those financed by the 
Global Fund now have a symbiotic relationship, and their 
success is mutually dependent in many countries. The 
Global Fund’s TB investments are focused on improving 
quality programs including the purchase and delivery 
of drugs and diagnostics—and U.S. bilateral programs 
complement them in planning and execution. The U.S. 
Government invested $1.35 billion in the Global Fund 
in FY 2017; based on the Fund’s portfolio, 18 percent of 
which is devoted to TB, the U.S. share of those grants 
was approximately $243 million.
WEB-BASED PLATFORM 
TRANSFORMS NATIONAL 
TB REGISTRY IN UKRAINE
The eTB Manager is a web-based 
platform that integrates data across 
all components of TB monitoring and 
control, which makes it a key tool in 
the implementation of the National 
Action Plan. With USAID support, 
since 2016 the e-TB Manager has been 
the official national TB registry used 
by the Ukraine National TB Institute, 
the Ministries of Health and Defense, as well as the penitentiary system. By the end of 2017, the system linked 
1,123 facilities with 2,332 active users who had already entered 247,940 TB cases and 53,804 DR-TB cases, or 92 
percent of all cases that year. The e-TB Manager software has been helpful in reducing the time doctors spend 
on recording and reporting data, which allows them to spend more time on patient care, and increases their 
participation in the monitoring-and-evaluation system. The e-TB Manager also has halved the time needed to 
switch patients from DS-TB treatment to MDR-TB treatment when they receive a diagnosis of DR-TB. Moreover, 
the e-TB Manager helps to improve the quality of care by providing a system to track the medications prescribed 
for each patient, which increases the rational use of medicines, and ensures more-effective treatment. To date, 
three of the National Action Plan countries use e-TB manager. 
Snapshot of the e-TB Manager module used in Ukraine. 
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Sub-objective 2.1.4: Improve the global 
availability and affordability of quality-assured, 
second-line drugs and improve country-level 
procurement and supply chain management 
systems
Access to second-line medications is essential for 
appropriate DR-TB care. USAID has therefore 
identified ensuring access to quality-assured 
second-line TB medications, traditionally a small and 
fragmented market, as one of its priority activities 
to achieve the goals of the National Action Plan. In 
2017, USAID continued its funding of the Global 
Drug Facility (GDF), which aids countries to secure 
quality-assured medications via a pooled-procurement 
mechanism. In 2017, the GDF ensured that quality 
TB and DR-TB medications were available in 111 
countries, decreased turnaround time from drug order 
to shipment to fewer than 60 days, and prevented 
drug stock-outs in 47 countries through its strategic 
rotating-stockpile mechanism. 
Figure 3: Actual number of Xpert 
MTB/RIF cartridges procured under 
concessional pricing
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7	 	GeneXpert	is	a	diagnostic	tool	that	tests	sputum	samples	for	the	presence	of	TB.	It	is	highly	accurate,	and	detects	difficult-to-diagnose	forms	of	TB,	
such as DR-TB and HIV-associated TB, in less than two hours, at more-accessible decentralized facilities. 
8	 	LPA	is	a	molecular	TB	test	used	to	detect	resistance	to	two	anti-TB	medications(fluoroquinolones	and	injectables),	within	24	hours
As the world’s leading supplier of TB diagnostics, GDF 
has played a key role in making new tools available 
to detect DR-TB. Since 2010, GDF has supplied 
GeneXpert commodities to 84 countries,7 and in 2017 
supplied 41percent of the 11.3 million Xpert MTB/
RIF cartridges procured globally. GDF currently serves 
as the main supplier of Xpert MTB/RIF cartridges 
for India and Pakistan’s NTPs. In 2017 alone, India 
procured 97 percent of its 2.5 million cartridges, as 
well as 507 new GeneXpert modules through GDF. 
GDF also supplies countries with line probe assays 
(LPA) for the rapid detection of first-and second-line 
drug resistance,8 which allows providers to screen 
patients with additional confidence that patients will 
be enrolled on the appropriate regimens. Given its 
large and increasing share of the TB-diagnostics market, 
GDF plays a vital role as market coordinator, by 
leading stakeholders and governments in negotiations 
with manufacturers for better pricing and servicing of 
diagnostics to improve patient access and ensure the 
efficiency and sustainability of laboratory networks.
To improve the quality and safety of DR-TB treatment 
in patients who receive novel medications and 
regimens, USAID piloted the implementation of active 
drug safety management and monitoring (aDSM) 
systems in five of the National Action Plan countries. 
In 2018, USAID will provide technical assistance with 
aDSM to improve management approaches and the 
safe use of DR-TB drugs to all 10 of the National 
Action Plan countries, as well as an additional 20 high-
burden TB countries. 
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OBJECTIVE 2.2: PREVENT MDR-TB 
TRANSMISSION
In 2017, USAID worked with Ministries of Heath, 
NTPs, and local partners to prioritize TB and DR-
TB activities to screen for high-risk patients; develop 
enhanced adherence programs; and support associated 
services in an effort to initiate treatment of individuals 
with DR-TB rapidly, not only to ensure they received 
appropriate care, but also to minimize the period 
during which they might transmit the disease to others. 
In four of the National Action Plan countries, USAID 
and CDC worked together to improve guidance for 
infection control and assist NTPs in addressing gaps 
and bottlenecks in healthcare facilities.
Sub-objective 2.2.1: Improve access to high-
quality, patient-centered MDR-TB services
The WHO recognizes active TB and DR-TB case 
finding among high-risk populations as a TB “best 
practice,” which USAID has initiated in several National 
Action Plan countries in 2017 to adapt a screening 
tool and to target TB-detection activities. 
Quality assessments of facility-and-community level 
DR-TB services, initiated in 2016 in National Action 
Plan countries, expanded in 2017. Regular site-
monitoring and treatment-cohort reviews assisted TB 
programs in optimizing the management of services 
and the delivery of care. 
Sub-objective 2.2.2: Enhance adherence to 
treatment for TB and MDR-TB
During the first year of the implementation of the 
National Action Plan, USAID developed Delivering 
Comprehensive Supportive Care to People with 
Drug-Resistant TB Guide to help improve adherence 
in patients who receive DR-TB treatment and services. 
The goal was not only to improve individual patient 
outcomes, but to render individuals non-infectious so 
9  The Building and Strengthening Infection Control Strategies (TB BASICS) is a four-phase initiative, developed by CDC, includes 1) training of 
healthcare workers in TB infection control; 2) baseline health-facility assessments and development of intervention plans; 3) implementation; and 4) 
monitoring	and	evaluation	through,	the	engagement	of	local	health	officials	and	healthcare	workers	to	encourage	commitment	to	the	initiative.
they cannot transmit the disease to others. In 2017, 
the care package pilot launched in China, Pakistan, 
South Africa and Ukraine to provide enhanced care 
and support services to 600 patients. Lessons learned 
through analysis of these pilots will lead to a modified 
package that will better serve patients, beginning in 
2018.
The treatment of DR-TB is challenging and complex 
for both patients and their families, and it can be 
difficult for patients to continue taking their medication 
for the very long period of time required. To minimize 
the burden of DOT on both patients and health 
systems, and to improve outcomes, USAID and CDC 
have introduced electronic technologies to assist daily 
adherence and treatment-monitoring. Video DOT, SMS 
reminders and other tools are currently being piloted, 
and USAID and CDC will adapt and expand them, if 
successful, in all National Action Plan countries in 2018. 
Sub-objective 2.2.3: Prevent the transmission of 
TB and MDR-TB within health-care facilities
Because TB, regardless of resistance pattern, is spread 
through the air, healthcare professionals who care 
for infectious TB patients are at particularly high risk 
of contracting the disease. The U.S. Government 
has introduced preventive strategies in National 
Action Plan countries that prioritize the well-being of 
healthcare workers through regular health assessments 
and active surveillance for TB. Building on the Year One 
successes of improving national infection control (IC) 
guidelines and curricula for healthcare workers, USAID 
and CDC provided technical assistance in Year Two to 
develop manuals and toolkits on specific IC technical 
areas, including IC administrative control and personal 
protection. USAID and CDC assisted countries with 
the implementation of national IC plans by using these 
tools, including the CDC TB BASICS program, a four-
phase TB IC initiative developed to assess and improve 
IC practice, in healthcare facilities through, a continuous 
quality improvement methodology.9
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GOAL 3: ACCELERATE BASIC AND APPLIED 
RESEARCH AND DEVELOPMENT TO COMBAT 
MULTIDRUG-RESISTANT TUBERCULOSIS
The National Institutes of Health (NIH) within HHS 
has a mission to fund and conduct domestic and 
international biomedical research on TB. Within 
NIH, the National Institute of Allergy and Infectious 
Diseases (NIAID) is the lead institute for TB research, 
complemented by programs supported through other 
NIH Institutes and Centers. This broad engagement 
provides opportunities to contribute strategically 
to key areas of science underpinning the discovery 
of new vaccines, drugs and diagnostics, as well as 
to conduct and support studies to identify product 
candidates and prepare them for clinical evaluation. 
Many research projects highlight the synergy between 
U.S. Government Agencies’ TB activities. Care 
strategies and tools developed with NIH support 
continue to be evaluated or implemented through 
USAID and CDC programs. For example, many 
products, such as the investigational anti-bacterial 
drug Pretomanid and diagnostic tool GeneXpert 
MTB/RIF, that are being tested in clinical trials or are 
implemented in TB endemic countries with CDC and 
USAID support, were developed with NIH funding. 
Observational international research cohorts, such 
as the Observational International Research Cohorts 
(RePORT) Network (http://www.reportinternational.
org), which is a cooperative strategy between NIH 
and interested governments, benefit from investments 
made by USAID, CDC and other U.S. Government 
agencies and are being used to initiate country-
based biomedical research. NIH contributes to TB 
product development thro ugh a variety of funding 
mechanisms. Since many global funders support TB 
research and development (R&D), NIH officials and 
scientists ensure that U.S. Government investments are 
optimally applied and complement other international 
programs. To facilitate coordination, NIH, USAID and 
CDC continue to participate in the WHO-led Funder’s 
Forum for TB R&D and the WHO Global TB Research 
Task Force. 
OBJECTIVE 3.1: INCREASE OPTIONS 
FOR PREVENTING ACTIVE TB, LATENT 
TB INFECTION AND TB TRANSMISSION
Due to the complexity of the host/pathogen 
interactions underlying the progression of latent 
MTB infection to active TB disease, developing 
new preventive strategies requires a thorough 
understanding of the biological mechanisms and 
dynamics of TB, and strategic support of critical 
product development and clinical testing activities. 
While products and care strategies that target persons 
at highest risk of developing transmissible forms of the 
disease are expected to have a significant impact on 
personal and public health, biomedical research and 
product development efforts are seeking to ensure 
that TB is preventable. 
Sub-objective 3.1.1: Advance research and 
development of novel vaccines
Building on a robust and broad TB portfolio of grants 
awarded to external institutions, and intramural 
projects conducted by NIH scientists, NIH continued 
and newly issued funding opportunity announcements 
in 2017 to expand its immunology and TB vaccine 
research portfolio. Critical topics remain: immune 
studies to identify markers that signal immune 
protection against infection or TB disease; exploration 
of the pathogen’s immune-evasive strategies as 
targets against which new vaccines can be directed; 
elucidation of mechanisms underlying the transition 
to active disease; and translational studies for the 
development of novel TB vaccine candidates. These 
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funding opportunities complement ongoing NIH-
supported projects that study a variety of vaccine 
and adjuvant approaches. NIH continues to provide 
resources to the research and product development 
community to facilitate translation of basic biomedical 
research findings into candidate products. These 
resources include microbial, biochemical and 
immunological reagents, bioinformatics tools and 
technologies to support data integration, and animal 
testing services and clinical trials capacity. NIH’s 
resources also contribute to the development of more 
predictive animal models and clinical trials to study 
the safety and efficacy of vaccine candidates. During 
the current reporting period, NIH conducted and 
participated in international workshops and seminars 
exploring contemporary topics in vaccine discovery 
and development and presented posters to highlight 
NIH-supported programs in TB, their relevance for 
vaccines and preventive strategies, and opportunities 
for accessing NIH resources. NIH staff also participated 
in discussions with other key funders/supporters of TB 
R&D and engaged with product developers to ensure 
that resources are optimally aligned to fill key gaps in 
vaccine development.
U.S. Government-supported research has contributed 
to product development and clinical research to 
explore novel approaches for the prevention of TB and 
to evaluate innovative vaccine concepts. Continued, 
iterative development and testing of candidate 
products is critical for advancing approaches developed 
in the laboratory and in animal models to those that 
will prevent human TB. U.S. Government interactions 
and collaborations with product developers and 
academic institutions will help ensure that best 
practices in TB R&D and product development can 
be leveraged by the research community when new 
vaccine, host-directed therapeutics and other adjunct 
approaches are investigated and will continue beyond 
the current reporting year.
Sub-objective 3.1.2: Support the development 
of methodologies to prevent transmission and 
development of TB and MDR-TB
In addition to basic, clinical, and translational 
biomedical R&D activities necessary for new product 
development, U.S. Government agencies (USAID, 
CDC and NIH) engage in patient-oriented research 
to inform prevention, treatment and management 
of TB. Strategies that were under investigation and 
included shorter courses of more effective therapies 
and treatment schedules for persons latently infected 
with MTB and effectiveness of prophylactic treatment 
to protect contacts of patients with MDR-TB. 
CDC, USAID and the President’s Emergency Plan 
for AIDS Relief (PEPFAR) supported a study of an 
enhanced infection control package on reducing TB 
transmission in healthcare facilities and communities 
in Vietnam and Thailand (EnTIC). This study has been 
completed with results expected in 2018. USAID 
began planning several collaborative projects to 
characterize transmission of MDR-TB in Kyrgyzstan 
and Moldova, countries with high rates of DR-TB, and 
continues its study evaluating a three-month, once-a-
week treatment intended to prevent the development 
of drug-resistant TB in HIV-infected individuals 
(WHIP3TB). NIH-supported a Phase III clinical trial 
of an ultra-short-course of rifapentine and isoniazid 
for HIV-infected individuals with latent TB in order to 
prevent the development of active TB disease. This 
trial has been completed, and highly promising data 
were presented at the March 2018 Conference on 
Retroviruses and Opportunistic Infections. 
Each country and community affected by TB presents 
unique challenges and opportunities for intervention. 
U.S. Government support is helping to meet the needs 
of individual countries by developing and implementing 
targeted strategies to effectively prevent transmission. 
Evaluating strategies, candidates and approaches in a 
broader range of diverse high-burden countries will 
require additional studies and continued investment at 
the local, national and global levels.
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OBJECTIVE 3.2: IMPROVE THE 
DIAGNOSIS OF DRUG-RESISTANT AND 
DRUG-SUSCEPTIBLE LATENT AND 
ACTIVE TB
Rapid and accurate diagnosis of acute and latent MTB 
infection, MDR-TB and XDR-TB is the cornerstone 
of TB care and control programs in the U.S. and 
worldwide. A variety of technologies are being 
developed and evaluated in countries where TB is 
endemic to confirm or rule out active TB and to 
quickly determine which antibiotics will constitute 
the most effective treatment regimen. Diagnosis 
of latent MTB infection offers the opportunity to 
provide patients with preventive therapy to lower 
their immediate risk of developing active – and often 
transmissible – TB. Diagnostic development involves 
research to identify what bacterial or biomarkers 
can be identified in sputum, blood or other body 
fluids or excretions and pairing those with novel, 
rapid technologies that can be utilized in healthcare 
settings where they are most urgently needed. Unique 
collaborations among multiple partners, including 
healthcare providers and TB control programs, are 
required to determine that a diagnostic test improves 
the accuracy and speed at which TB patients of all ages 
can be identified and offered effective treatment. 
Sub-objective 3.2.1: Support the development of 
new tools and approaches for detection of drug-
resistant TB
NIH currently supports research on a broad and 
diverse range of technologies and approaches aimed 
at improving the identification of DS-TB and MDR-
TB/XDR-TB, as well as the identification of human 
biomarkers suitable to determine whether a person 
has MTB infection and may be at risk for developing 
active TB disease. A continued area of focus is the 
creation of comprehensive datasets that give insight 
into the diversity of the biology and drug resistance 
profiles of MTB strains and how they affect patients. 
One example is the NIH-supported “TB Portals” 
Program (https://tbportals.niaid.nih.gov), which is a 
web-based, open-access repository of socioeconomic/ 
geographic, clinical, laboratory, radiological and genomic 
data from patients with DR-TB to facilitate multi-
national collaboration for data sharing and analysis. 
NIH and CDC continue to support and participate 
in collaborations among international researchers to 
sequence and process genomes of MTB isolated from 
patients in Africa, Asia, Europe, Latin America and the 
Middle East. Data from several thousand bacterial 
isolates are being integrated into global databases 
benefiting the development of molecular diagnostic 
technologies. To facilitate integration of promising new 
diagnostics at the most critical stage of patient care, 
U.S. Government Agencies (NIH, USAID and CDC) 
also support clinical evaluations of and feasibility testing 
of new diagnostic tools. These biomedical and clinical 
programs are complemented by studies to strengthen 
the existing approaches to TB diagnosis in high-burden 
countries. This ensures that barriers to effective 
diagnosis are identified and best practices are in place 
to identify and refer patients for effective therapy. A 
program of stepwise activities leading to the confirmed 
diagnosis of TB is the platform on which new tools 
and approaches will be evaluated and is a cornerstone 
to successful rollout of new diagnostics. With the 
emergence of new diagnostic platforms, strong 
collaborations among clinicians, public health scientists, 
bioinformatics specialists and medical diagnostic 
developers provide opportunities for development and 
strengthening of reference laboratories in TB endemic 
countries to evaluate promising new diagnostic tests.
Sub-objective 3.2.2: Support research to identify 
biological markers to help detect latent TB and 
progression to active TB in children and adults
NIH’s Tuberculosis Research Unit Network (TBRU-N) 
and other ongoing projects are identifying blood-
based biomarkers that may be useful in differentiating 
between latency and persistence of TB in individuals 
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in endemic countries. To enable coordinated and 
comparable research in TB endemic countries, the 
NIH co-funded RePORT Networks operate under 
standardized protocols and are contributing critical 
resources to NIH-funded projects that are studying TB 
in endemic countries. In collaboration with NIH, CDC 
continues to contribute TB samples to the Consortium 
for Tuberculosis Biomarkers (CTB2), which may speed 
the clinical trials of new drugs and facilitate the search 
for biomarkers in adults and children that will help 
predict or identify progression from MTB infection to 
TB disease. 
The establishment of longitudinal cohorts and 
increased research capacity in endemic countries 
created platforms for collaborative research in human 
TB in the context of country specific co-infections, 
such as HIV and co-morbidities such as diabetes. To 
maximize the potential of international collaborative 
research, continued dialogue among specialists from 
all scientific disciplines – from basic to clinical to 
implementation/operational research – needs to be 
encouraged and facilitated.
OBJECTIVE 3.3: IMPROVE TREATMENT 
OPTIONS FOR DRUG-SUSCEPTIBLE 
AND DRUG-RESISTANT TB
Improving treatment options for TB also requires 
engagement across the full spectrum of TB 
research, from basic science to implementation. 
U.S. Government agencies are contributing multiple 
kinds of support, expertise and research to support 
preclinical and clinical research to enable short-, 
medium- and long-term improvement of TB care. 
While global and domestic recommendations 
for treatment of DS-TB and DR-TB are available, 
continued progress is needed and is ongoing. The 
use of key drugs within these regimens is being 
optimized, new drugs are being studied for their 
ability to shorten therapy and provide safer treatment 
options, and completely new, innovative regimens and 
treatment approaches are being developed that would 
dramatically impact patient care. 
Sub-objective 3.3.1: Improve the use of existing 
TB drugs for treatment of drug-susceptible and 
drug-resistant TB
U.S. Government agencies (USAID, CDC, and 
NIH) are conducting studies to assess the utility 
and effectiveness of several therapeutic regimens 
comprised of licensed and novel drugs that may 
result in fewer serious side effects and/or shorter 
treatment durations for patients with MDR-TB. NIH-
funded studies designed to evaluate higher doses 
of key drugs for first and second line TB therapy 
are nearing completion and publication of data. The 
USAID-supported Standardised Treatment Regimen 
of Anti-tuberculosis Drugs for Patients with MDR-TB 
(STREAM) randomized clinical trial suggests that the 
efficacy of a nine-month MDR-TB treatment regimen 
composed of existing TB drugs is similar to the efficacy 
of the current 20-24 month regimen. These studies 
also contribute to capacity building with other nations’ 
TB programs and help ensure that the most recent 
scientific findings are integrated into treatment policies. 
Furthermore, to facilitate implementation of novel 
regimens, USAID is also supporting the development 
and introduction of ancillary packages of care that 
support MDR-TB patients during treatment and help 
them complete therapy. NIH collaborated on several 
workshops designed to identify new targets against 
which TB drugs can be directed and to develop 
best practices for preclinical development of all new 
treatment regimens. 
Sub-objective 3.3.2: Enhance knowledge to 
enable optimal and safe use of newly registered 
TB drugs
In 2012 and 2014, biomedical R&D on TB resulted 
in the licensure of the first two new drugs, BDQ 
and DLM, in decades. The integration of these new 
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drugs into existing regimens to replace or improve 
therapy requires efficacy and safety studies to ensure 
that treatment is effective and that patients benefit 
from new drugs. During 2017, USAID continued to 
contribute to the second phase of the STREAM trial, 
which includes BDQ, a newly registered drug, and 
will recruit patients in 10 countries. The USAID co-
sponsored Nix-TB trial also delivered promising results 
and is being followed by additional co-sponsored 
trials to further optimize this promising approach of 
immediately testing regimens including novel drug 
candidates, rather than licensing individual drugs that 
are then combined with or added to existing therapies. 
An NIH-sponsored trial will commence in 2018 to 
evaluate safety and tolerability of BDQ in infants, 
children, and adolescents who may or may not be 
co-infected with HIV, contributing data for the safe use 
of this drug in these important populations. As new 
drugs licensed for TB become available, clinical trials 
need to be conducted to evaluate how they perform 
in combination and determine what side effects may 
occur. If these new drugs are to be used for TB/HIV 
co-infected individuals, then clinical studies are needed 
to determine whether there are drug-drug interactions 
with antiretrovirals. The USAID-co-sponsored BDQ 
donation program also prioritizes support for 
pharmacovigilance and facilitates scale-up of the use of 
this drug in TB control programs.
Sub-objective 3.3.3: Develop novel drugs and 
shorter regimens to treat drug-resistant TB and 
improve the selection of drug candidates for 
clinical trials
Development of new chemical entities requires 
a thorough understanding of the biology of MTB, 
where it resides in organs, and how best to target 
drugs to these locations for maximum effectiveness. 
Anti-infective strategies are being complemented 
by therapies that enhance the ability of the patient’s 
immune system to limit the destructive effects of TB 
on organs, and NIH is supporting several programs 
in host-directed therapy. NIH is also continuing 
to support preclinical studies in animals and the 
laboratory in order to select the most promising new 
chemicals for further advancement. NIH-sponsored 
scientists continue to make advances in drug discovery 
through participation in global drug development 
consortia, which are emerging as effective models 
for academic-pharmaceutical collaborations. These 
research partnerships are increasingly utilizing rational, 
pharmacologically-driven approaches to drug discovery, 
development of animal models, regimen selection and 
clinical trial design to improve the state of the science 
of TB drug discovery and lower risks for product 
developers. 
Significant innovation has occurred, and important 
research discoveries are now being applied to the 
preclinical assessment of new chemicals and regimens. 
To help ensure that these approaches will contribute 
in a meaningful way to the best practices for drug 
development, long-term investment and sustained 
research partnerships among U.S. Government 
agencies, academia, not-for-profit and for-profit 
organizations will be important.
OBJECTIVE 3.4: INCREASE CAPACITY 
TO CONDUCT BIOMEDICAL AND 
CLINICAL RESEARCH ON TB IN  
TB-ENDEMIC COUNTRIES
Research studies involving human volunteers are 
the cornerstone of clinical biomedical research and 
require close collaboration with TB-endemic countries 
to be successful. To ensure that U.S. Government 
investments in biomedical research have tangible 
benefits for communities worldwide, NIH, CDC and 
USAID continue to support partnerships with host 
country scientists and universities, and local affected 
communities, as well as bilateral programs with 
governments to advance research capacity building 
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and investigator training. The need to engage countries 
with a significant burden of TB to support all aspects 
of research is articulated in the third pillar of the 
WHO’s End TB Strategy. Because general infectious 
disease training benefits scientists who conduct TB 
research by improving their research and clinical skills, 
numerous NIH funding opportunities for training 
were issued during the reporting period that are not 
specifically directed toward TB but will have positive 
benefits for TB programs. To help facilitate applications 
for NIH funding opportunities, NIH continues to 
provide training in grant writing, financial administration, 
bioethics and implementation research, particularly 
through its ongoing Human Heredity and Health in 
Africa (H3Africa) program. Infrastructure developed 
with USAID and CDC support is leveraged by 
local scientists in international research projects and 
collaborations in NIH-supported grants.
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CONCLUSION
The U.S. Government Departments and Agencies charged with implementing the National Action Plan continue 
to make notable progress towards achieving the Plan’s established milestones. Overall, results from improving 
care and strengthening programs as part of the implementation of the National Action Plan in Year Two showed 
slower progress than Year One, with the exception of the treatment of XDR-TB, which increased sizably. 
While National Action Plan countries achieved significant progress in updating their DR-TB treatment plans to 
include BDQ, or transitioned to the use of the STR as appropriate, observed rates in the areas of detection and 
treatment remained relatively unchanged, in line with the global trends observed in 2017. Increased political will 
within the target countries and access to additional resources will be required for the rapid scale-up needed in 
2018, and through the rest of the Plan to achieve the milestones laid out for Year Three. 
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APPENDIX:  
MILESTONES AND ADVANCES
GOAL 1  
Objective 1.1 Upgrade TB surveillance to ensure complete and accurate detection of drug-resistant TB 
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
Identify common language and 
protocols for reporting drug 
resistance to anti-TB drugs.
 § Development of standardized reporting 
underway.
 § The U.S. domestic TB surveillance system is being 
upgraded to be able to collect and report the 
results	of	new	methods	for	the	identification	of	
resistance. The molecular drug susceptibility testing 
reporting (MDSTR) form has been successfully 
developed and tested within the National TB 
Surveillance System Case Reporting (NTSSCR) 
system. CDC is in the beginning stages of adding 
pilot users to the system for beta testing the 
MDSTR form. 
Identify requirements for creating 
electronic links between clinical 
laboratories and TB surveillance 
programs at the Federal, State 
and local levels.
 § CDC is in the beginning stages of developing 
and implementing HL7 standardized coding for 
Electronic Laboratory Reporting (ELR) into state 
surveillance systems as well as standardized coding 
for electronic transmission from state surveillance 
systems and CDC labs into the NTSSCR MDSTR 
data collection system. 
Objective 1.2 Strengthen State and local capacity to prevent transmission of drug-resistant TB
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
Work with the National TB 
Controllers Association to 
develop surge capacity for 
controlling transmission of drug-
resistant TB.
 § Finalizing new metrics for tracking TB 
transmission that can be applied to drug 
resistant TB as well as drug-sensitive TB.
 § Expanded data collection for drug susceptibility 
testing results to be included in new version of 
Report	of	Verified	Case	of	Tuberculosis	(RVCT).	
Explore ways to increase 
staffing	at	State	and	local	health	
departments during TB contact 
investigations.
 § Unable	to	address	surge	capacity,	increased	staffing,	
or development of other new tools without 
additional funding.
Objective 1.3 Ensure that patients with drug-resistant TB receive treatment until cured
Sub-objective 1.3.1 Explore the potential use of a national TB stockpile to ensure the availability of TB medicines and 
screening tests
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
CDC will explore the 
development of a National TB 
Stockpile that could store and 
rotate TB supplies that can be 
ordered by State and local TB 
programs.
 § Stockpile, managed by the DHHS Supply 
Service Center, is operational in the event of 
a national drug shortage.
 § The TB Emergency Drug Stockpile has been 
successfully maintained. There has been no national 
shortage of TB drugs, so the stockpile was not 
utilized in Year Two. 
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Sub-objective 1.3.2 Explore options for providing care for persons with MDR-TB or XDR-TB who do not have a medical home
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
CDC and State and local TB 
programs will work together on 
plans for completion of therapy 
once MDR-TB or XDR-TB 
patients are released from a 
hospital.
 § Clinical trial design to evaluate electronic 
directly observed therapy (eDOT) for treating 
TB disease.
 § A randomized trial of Electronic Directly Observed 
Treatment (eDOT) is underway. Informed consent 
forms	and	study-specific	data	collection	forms	
were created in collaboration with partners at the 
NYC Department of Health and Mental Hygiene’s 
Bureau	of	TB	Control.	The	study	specific	database	
is under development. The non-inferiority study 
is currently recruiting study participants. Data 
collection forms for the economic evaluation were 
finalized	and	data	collection	in	the	selected	sites	
has begun.
Sub-objective 1.3.3 Improve completion of therapy for persons who travel in or out of the United States while on treatment 
for TB disease
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
CDC and others will explore 
ways to strengthen medical 
management of transnational TB 
disease cases.
 § Evaluation of binational (U.S.-Mexico) case 
definition	for	surveillance	system	in	progress.
 § The	Surveillance	Definition	for	Binational	TB	Cases	
Workgroup	has	developed	a	revised	definition	for	
binational TB cases that will be published in 2018.
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GOAL 2 
Objective 2.1 Improve access to high-quality, patient-centered diagnostic and treatment services
Sub-objective 2.1.1 Strengthen the capacity of national TB laboratory networks to diagnose and treat TB and MDR-TB
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID and CDC will work with 
up to 10 countries to develop 
comprehensive national TB/
MDR-TB laboratory strategic 
plans addressing provision and 
placement of services at each 
level, as part of each country’s 
National TB Strategic Plan.
 § The NTPs of Burma, India, Indonesia, 
Kazakhstan, Pakistan, Philippines, South Africa, 
and Ukraine have NLSPs that address TB and 
MDR-TB.
 § USAID developed a framework for assessing 
TB laboratory and diagnostic networks 
in multiple countries using tools adapted 
through a USAID-led comprehensive 
international review of Nigeria’s TB diagnostic 
network in March 2016.This framework is 
a key step towards prioritizing and planning 
laboratory strengthening and monitoring.
 § In Nigeria, USAID and CDC developed an 
operational plan/work plan in response to the 
TB diagnostic network assessment, including 
revisions to the DR TB diagnostic algorithm.
 § Mapping of diagnostic networks is also 
underway in several countries in sub-Saharan 
Africa, and the U.S. Government is working 
with the Global Laboratory Initiative (GLI) 
and GLI Africa to promote best practices and 
accelerate scale up of MDR-TB diagnostics in 
priority countries.
 § USAID and CDC supported sub-Saharan 
African and Asian countries to complete national 
inventories of their GeneXpert instruments as a 
first	step	toward	optimizing	testing	networks	and	
improving patient access to rapid diagnostic and 
resistance-testing services for rifampicin (RIF).
USAID-led achievements:
 § Worked with NTPs and bilateral partners 
to create NSLPs during Year Two of the 
implementation of the National Action Plan. By 
the end of Year Three, we expect nine out of 
the 10 National Action Plan countries will have 
national lab plans developed and approved for 
implementation.
 § A comprehensive assessment of the TB-diagnostic 
network in India was conducted to review 
the diagnostic network, current practices and 
algorithms holistically; identify challenges that 
prevent the overall diagnostic network from 
performing	efficiently	and	effectively;	and	propose	
evidence-based interventions to improve the 
overall ability of the TB-diagnostic network to 
meet the goals and targets of India’s ambitious 
new National Strategic Plan (NSP). As a result 
of the assessment, India is revising its NLSP and 
developing operational plans at national and State 
levels, with a focus on strengthening the diagnosis 
of MDR-TB. 
 § In Ukraine, a team of domestic and international 
experts worked together to create a NSLP, based 
on recent recommendations of the WHO. In-depth 
assessment and country visits have helped to shape 
the document and set ambitious targets and goals 
for	the	next	five	years.	
 § In the Philippines, USAID worked with the NTRL 
to introduce new technology for the rapid 
detection of TB and develop a plan for country 
scale-up by leveraging both national and funding 
and resources from the Global Fund. 
 § USAID	financed	the	development	of	a	specimen-
referral toolkit to help countries identify gaps 
within	their	networks	and	solutions	for	an	efficient	
and integrated specimen-referral system.
 § India leveraged Global Fund and USAID funding 
to complete a trial of a domestically-developed 
diagnostic, Truenat that was endorsed as a 
molecular-test replacement for smear microscopy. 
A second-step assay to detect resistance to RIF) is 
currently undergoing optimization studies.
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CDC-led achievements:
 § CDC began work in countries in Africa and Asia 
that are part of PEPFAR, to complete national 
inventories of their GeneXpert instruments as a 
first	step	towards	optimizing	testing	networks	and	
improving patient access to rapid diagnostic and 
RIF resistance testing services.
 § CDC is strengthening the capacity of national and 
intermediate TB reference laboratories to provide 
quality testing and supervisory services in India and 
China through:
 § Successful transfer and ongoing national scale-
up of the agency-developed Xpert MTB/RIF 
external quality assurance program to one 
national reference laboratory in India.
 § Implementation of a structured, mentorship-
based quality management system improvement 
program to support national (India) and 
intermediate (India and China) reference 
laboratories work toward international 
accreditation.
 § CDC supported the establishment and validation 
of whole genome sequencing technology at a 
NTRL in India for enhanced characterization of 
DR-TB cases and DR-TB surveillance.
Year Three Milestones  Progress towards Year Three to Five Milestones 
USAID and CDC will work with 
up to 10 countries to implement 
laboratory strategic plans to 
improve diagnostic capacity from 
the central to the peripheral 
level as part of each country’s 
National TB Strategic Plan. 
 § Development	of	national	laboratory	strategic	plans	is	the	first	step	towards	improvement	of	TB	
laboratory capacity in a country. As TB diagnostic networks consist of national, regional, provincial 
and district-level laboratories, appropriate decentralization and support to all levels of the network is 
needed. USAID worked in Year Two with NTPs and local partners to optimize diagnostics throughout 
the network, especially peripheral-level laboratories, to ensure that TB diagnostic instruments are 
running, have the necessary commodities, and are delivering real-time results to inform appropriate 
patient management. An example of USAID’s approach to optimizing diagnostics throughout the 
network can be seen through the introduction of “connectivity” solutions whereby instruments that 
produce electronic results are connected with the TB program to monitor instrument utilization and 
commodity stock, analyze performance of diagnostic tests, and receive timely results about new TB 
and DR-TB patients. USAID works with the national partners to further scale up laboratory plans, 
follow-up	with	national	and	international	standards	and	demonstrate	progress	towards	five-year	goals.	
 § USAID and CDC are working with the GLI and GLI Africa partnerships to develop and implement 
guidance on key diagnostic network strengthening components, inventory country NSLPs and develop 
best practices on plan development.
Sub-objective 2.1.2 Expand and strengthen national MDR-TB care and treatment capacity to optimize the use of current and 
novel regimens
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID	will	work	with	up	to	five	
countries to introduce a new 
MDR-TB drug (BDQ, DLM or 
both).
 § USAID supported NTPs in Burma, India, 
Indonesia, Kazakhstan, Pakistan, Philippines and 
South Africa to introduce BDQ for treatment 
of MDR-TB. This support encompassed a 
wide variety of activities; for example, revision 
of NTP treatment guidelines to include BDQ, 
training of clinicians on the appropriate use 
of BDQ, coordination with pharmaceutical 
regulatory agencies to facilitate importation 
and development of systems to monitor 
adverse events.
 § Additionally, Burma and South Africa 
introduced DLM in limited research 
conditions.
 § USAID further expanded access to BDQ and 
DLM, building upon the introduction of the drugs 
into seven of the 10 National Action Plan countries 
during Year One. 
 § Collaboration between South Africa’s Department 
of Health, Johnson & Johnson and USAID resulted 
in National Action Plan countries enrolling 4,277 
DR-TB patients on BDQ and on DLM. The 
majority of the patients enrolled on BDQ. More 
than 85 percent of the patients enrolled on BDQ 
were enrolled in South Africa.
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USAID will work with up to 10 
countries to introduce and scale-
up new DR-TB drugs.
 § South Africa was an early adopter of BDQ 
for treatment of DR-TB. Since the inception 
of the Bedaquiline Donation Program, almost 
4,000 patients received the drug as part of 
their treatment regimen. Technical assistance 
provided by USAID to the NTP greatly 
increased access to the drug.
 § Significant	progress	was	made	by	USAID	during	
Year Two in all of the National Action Plan 
countries. Ninety percent of National Action Plan 
countries expanded their BDQ treatment sites. In 
Burma, India, Indonesia, Nigeria and Ukraine, the 
number of BDQ treatment sites is estimated to 
have tripled. 
 § With USAID support, GDF, through the 
Bedaquiline Donation Program, increased the 
global supply of BDQ from 1,487 packs in 2016 to 
more	than	8,000	packs	in	2017,	a	five-fold	increase.	
In 2017, 2,689 packs of DLM were shipped globally; 
more than 30 percent of these packs were shipped 
to National Action Plan countries. 
Year Three Milestones  Progress towards Year Three to Five Milestones 
USAID will work with up to 
10 countries to introduce 
shortened MDR-TB regimens 
 § STR for patients with DR-TB is a novel approach to treatment. Patients receiving STR are treated for a 
shorter duration, experience fewer side effects and have better treatment success rate than observed 
with conventional regimens. STR is also approximately 3-4 times cheaper than the conventional 
regimen. 
 § In 2016, during the Year One of the National Action Plan implementation, the Philippines was the only 
country that had introduced STR with 272 DR-TB patients enrolled on treatment. In 2017, USAID 
worked with NTPs and local partners to bring this novel regimen to all National Action Plan countries. 
As a result, three additional National Action Plan countries (South Africa, Nigeria and Indonesia) have 
introduced STR and approximately 5,600 patients have been enrolled on treatment. 
 § In 2018, as many as nine out of 10 National Action Plan countries are expected to introduce STR, and 
more than 10,000 will be enrolled on treatment. 
USAID will develop quality 
facility and community-based 
MDR-TB care and treatment 
services
 § In September 2017, USAID convened a workshop for 68 participants from the 10 National Action 
Plan countries. The workshop presented current best practices in DR-TB community care and 
support with the goal of developing national roll-out plans for each of the 10 National Action Plan 
priority countries. Through a collaborative approach, workshop attendees were empowered to create 
context-specific	action	plans	for	implementing	aspects	of	community-based	DR-TB	care	within	their	
country, including relevant timelines, quality improvement strategies, and monitoring and evaluation 
strategies.
 § CDC supported a counseling program in Mumbai to improve adherence and retention of DR-TB 
patients on treatment. Over 2,000 patients have received adherence counseling, as well as repeated 
home visits through this program. 
 § CDC led a demonstration project of the ECHO platform for DR-TB treatment at one national 
treatment facility in New Delhi.
 § It is expected that by the end of Year Three of the National Action Plan, all 10 countries will initiate or 
scale	up	community-based	programs	targeting	DR-TB	patients	and	their	families.	As	a	result,	significant	
numbers of people globally will have access to patient-centered service.
Sub-objective 2.1.3 Strengthen TB and MDR-TB surveillance
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID will enhance tracking 
of MDR-TB disease burden 
and surveillance data for 
dissemination.
 § USAID developed and provides ongoing 
financial	and	technical	support	to	the	WHO’s	
Tuberculosis Monitoring and Evaluation (TME) 
Unit to perform annual collection and analysis 
of TB data, including routine data on MDR-TB 
in over 200 countries.
 § USAID continues to develop and provide ongoing 
financial	and	technical	support	to	the	WHO’s	
Tuberculosis Monitoring and Evaluation (TME) 
Unit to perform annual collection and analysis of 
TB data, including routine data on MDR-TB in over 
200 countries.
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CDC will assist one country in 
the completion of an inventory 
study to determine gaps in the 
TB surveillance system.
 § CDC supported China’s National Center 
for TB (NCTB) to conduct a pilot inventory 
study.
 § In nine provinces, lessons learned were 
reviewed, and a standardized process for 
routinely matching laboratory, hospital, and 
surveillance records to identify TB cases that 
were not reported to the national system 
was developed. In 2016, CDC assisted the 
NTP in the Philippines in planning its national 
inventory study to measure the level of 
under-reporting of diagnosed TB cases to the 
surveillance system. 
 § USAID also provided technical assistance to 
the State TB program in Lagos, Nigeria, to 
plan an inventory study.
 § The CDC supported the China National Center 
for TB’s (NCTB) pilot inventory study which 
was completed in Fall 2016. Overall, 19 percent 
of cases were not registered within six months, 
with a variation of 3-37 percent across counties. 
These	findings	helped	the	NCTB	realize	the	need	
for routine record linkage between the national 
TB surveillance system and health facility and 
insurance systems. Using the lessons learned from 
this project, a set of tools including a computer 
program to match cases have been developed and 
shared with six counties. 
 § USAID is providing ongoing support for an 
inventory study in Lagos, Nigeria, to assess the 
level of underreporting by private sector providers. 
Fieldwork is complete, with 680 facilities and 511 
providers assessed, and data analysis is ongoing. 
Results and recommendations are expected to be 
available by the end of 2018.
Year Three Milestones  Progress towards Year Three to Five Milestones 
USAID and CDC will work with 
up to 10 countries to implement 
standards and benchmarks to 
improve surveillance and vital 
registration systems to directly 
measure TB burden.
 § Standards and benchmarks (S&B) have been used as a part of the NTP review process as well as 
during prevalence surveys. It is expected that at least eight countries will have S&B benchmarks 
implemented by the end of December 2018. As of December 2017, the following countries have 
completed the S&B checklist: Burma (2016), Indonesia (2017), Kazakhstan (2017), Nigeria (2017), 
Pakistan (2016), Philippines (2017), South African (2015) and Ukraine (2014). China is currently 
undertaking this with support from WHO/TME and CDC; India will complete their checklist in 2018.
USAID will work with up to 
five	countries	to	introduce	and	
scale up patient-based electronic 
recording and reporting systems. 
 § National Action Plan countries have various approaches for electronic data collection and analysis. 
In several countries, an e-TB Manager tool, which was developed several years ago by USAID and 
partners, has been fully implemented and received government support for scale up e.g. Ukraine. In 
other countries, local government has been investing in developing electronic tools to track several 
diseases, including TB. 
 § India	continues	to	develop	its	e-Nikshay	case-based	notification	system.	USAID	is	planning	to	support	
e-Nikshay’s expansion to include Programmatic Management of Drug-Resistant Tuberculosis (PMDT) 
and direct connectivity to Xpert.
 § By the end of Year Three, it is expected that all 10 National Action Plan countries will either introduce 
or fully scale up electronic recording and reporting systems for TB.
Sub-objective 2.1.4 Improve the global availability and affordability of quality-assured, second-line drugs and improve  
country-level procurement and supply chain management
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID will support the 
continued development and 
maintenance of a global supply 
of affordable, quality-
assured, second-line drugs to 
ensure access to life-saving drugs.
 § USAID has provided ongoing support to the 
GDF to maintain a strategic rotating stockpile 
(SRS) of second-line medications that NTPs 
can access to ensure timely and affordable 
supply of second-line drugs at all times. The 
SRS is also available for emergency orders. 
The GDF is able to turn around requests to 
the SRS very quickly to ensure that patients 
can stay on life saving treatment. Additionally, 
USAID works with the GDF to improve 
procurement and distribution systems in 
countries.
 § USAID continues to support GDF, an organization 
responsible for procurement and delivery of anti-
TB medicines globally. 
 § In 2017, 111 countries were served by the GDF. 
 § GDF delivered nearly $304 million of TB products 
(first-line	drugs,	second-line	drugs	and	diagnostics)	
to 119 countries in 2017 an almost 50 percent 
increase compared to 2016.
 § Additionally, the turnaround time from request to 
shipment decreased from four to six months to 
less than 60 days, and in coming years, GDF will 
work to reduce the lead time even further.
 § Thanks to price negotiation by GDF, the price of 
clofazimine has been reduced by 11 percent in 
the	first	quarter	of	2017,	and	an	additional	price	
reduction is expected in 2018.
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Year Three Milestones Progress towards Years Three to Five Milestones
USAID will work with up to 
10 countries to develop and 
implement pharmacovigilance 
systems to monitor adverse drug 
reactions to all second-line drugs 
in conjunction with the roll-out 
of the bedaquiline donation 
program and ongoing drug 
management support.
 § aDSM is a pharmacovigilance approach which is used in the TB and DR-TB communities. aDSM was 
first	introduced	by	the	WHO	in	2015.	USAID	technical	assistance	to	countries	to	adopt	and	pilot	the	
approach started in 2016 and continues. 
 § In April 2017, USAID convened key stakeholders from Burma, China, India, Indonesia, Pakistan, Papua 
New Guinea, Philippines, South Korea, Thailand and Vietnam for the Asia Regional Pharmacovigilance 
Workshop to initiate implementation of aDSM activities with the focus on new TB drugs and new 
regimens. Following the workshop, countries initiated aDSM pilots and planning for further scale-up 
will continue through 2018.
 § In 2018 USAID will continue working with the National Action Plan countries to plan two additional 
aDSM workshops.
USAID will work with up to 
seven countries to introduce 
and scale up an MDR-TB early 
warning drug procurement and 
management systems to prevent 
stock-outs.
 § QuanTB is the electronic tool developed by USAID and partners to support countries as they track 
drug	stock	at	national	and	regional	levels.	The	tool	allows	for	accurate	quantification	of	drug	orders	
and provides easy visualization of the system. As of December 2017, four countries have implemented 
QuanTB at the national level: Nigeria, Pakistan, Philippines and Ukraine. 
 § In 2018, USAID will provide technical assistance to additional countries to launch the tool. 
Objective 2.2 Prevent MDR-TB Transmission 
Sub-objective 2.2.1 Improve access to high-quality, patient-centered MDR-TB services
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID will work with up to 
10 countries to validate and 
introduce a risk prioritization 
screening tool.
 § In Burma, Indonesia, Kazakhstan, Nigeria and 
South Africa, USAID implemented a risk 
prioritization tool to identify the important 
populations and screening strategies to 
maximize detection of additional TB cases that 
might not otherwise be found.
 § Additional National Action Plan countries have 
implemented a similar prioritization exercise and 
USAID expects to review these alternative tools 
and corresponding results by the end of Year Three.
Year Three Milestones Progress towards Years Three to Five Milestones
USAID will work with up to 10 
countries to introduce and/or 
scale up patient-centered TB and 
MDR-TB quality service delivery 
site monitoring.
 § Site monitoring for the quality of DR-TB care delivery is one of the tools at the NTPs used to assess 
and	improve	the	quality	of	care	provided.	USAID	will	start	implementation	of	intensified	quality	
assurance DR-TB programs in early 2018 and expect to cover at least nine countries by the end of 
Year Three. 
Sub-objective 2.2.2 Enhance adherence to TB and MDR-TB treatment
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID will develop generic 
ancillary care packages (e.g., 
services and supplies not directly 
related to treatment, but which 
enable patients to continue 
therapy, such as pain or nausea 
medicine, food rations and 
supportive services) for MDR-
TB patients.
 § USAID developed an ancillary care package 
to identify key services and interventions 
needed to support MDR-TB patients 
throughout the diagnosis and treatment 
processes. During Year One, USAID 
undertook a survey of patients, providers 
and technical partners to identify the key 
barriers to successful MDR-TB diagnosis and 
treatment.
 § During Year Two of National Action Plan 
implementation, USAID launched the pilot 
program of DR-TB care package in four countries: 
China, Pakistan, South Africa and Ukraine. Seven 
hundred DR-TB patients were enrolled on 
comprehensive, patient-centered care support.
Year Three Milestones Progress towards Years Three to Five Milestones
USAID will work with up to 
10 countries to implement and 
scale up ancillary care packages 
to improve MDR-TB patient 
treatment outcomes.
 § By	July	2018	the	pilot	activity	will	be	finalized	and	results	will	be	assessed.	USAID	will	report	on	
efficacy,	feasibility	and	cost-benefits	of	the	DR-TB	care	package	provided	and	collect	lessons	learned.
 § Based on the results and experience of the DR-TB care package pilot in China, Pakistan, South Africa 
and Ukraine, USAID will further expand the approach into six additional countries.
 § A workshop is planned for September 2018 in Kazakhstan and will target NTP staff, civil society and 
patient groups from Burma, India, Indonesia, Kazakhstan, Nigeria and the Philippines.
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USAID will work with up to 
10 countries to implement 
and scale up a TB adherence 
assessment tool.
 § USAID has been consulting with the WHO on the methods to better track the adherence of TB and 
DR-TB patients and to improve quality of treatment overall. In early January 2018, the WHO released 
the Handbook for the use of digital technologies to support tuberculosis medication adherence.
 § During	2018,	USAID	will	work	with	five	countries	and	pilot	novel	electronic	tools	to	monitor	
adherence to TB treatment and remote support to TB patients.
 § CDC has supported the Mumbai-based SAKSHAM counseling program in India, which provides 
counselors to follow-up MDR-TB patients to encourage adherence, improve retention and provide 
guidance for referrals in the case of adverse events. Over 2,700 patients have been provided 
counseling	through	SAKSHAM.	The	first	cohort,	approximately	700	patients,	showed	a	retention	rate	
of 70 percent at the end of 12 months of MDR-TB treatment.
Sub-objective 2.2.3 Prevent the transmission of TB and MDR-TB within health care facilities
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID will work with up to 
10 countries to develop quality 
national infection control 
guidelines.
 § Building on the existing TB portfolio, USAID 
has supported the development of quality 
national infection control guidelines in Burma, 
India, Indonesia, Kazakhstan, Nigeria, Pakistan, 
South Africa and Ukraine. All infection 
control guidelines are based on the WHO-
recommended standards and guidelines, a 
subset of which is integrated into the USAID 
supported FAST strategy, as requested by 
NTPs.
 § Through the End TB Transmission Initiative (ETTi) 
USAID and CDC are supporting the National 
Institute of Tuberculosis and Respiratory Disease 
(NITRD) in New Delhi, India, in applying the 
principles of airborne infection control (AIC). A 
facility-wide	risk	assessment	identified	enhancements	
to NITRD’s infection prevention and control (IPC) 
plan starting with administrative controls. After the 
successful implementation of the administrative 
controls, the next phase will be to enhance the 
facility’s AIC included environmental controls 
to supplement natural ventilation. The NITRD 
demonstration project results will be used to 
refine	guidelines	for	monitoring	safety	and	output	
performance	of	the	fixtures.	
 § USAID supported biosafety cabinet testing and 
maintenance training, through the WHO, with 
participants from Ukraine and helped with the 
development of TB laboratory maintenance guidance.
 § USAID supported the building of capacity in TB IPC 
consultants through the AIC Summer Course on 
Building Design and Engineering Approaches to Airborne 
Infection Control, mentoring visits for selective would-
be consultants, and the TB Design Roster to connect 
projects in need of consultants with individuals who 
have undergone special training. Together, these three 
interrelated activities address the inability of projects 
to identify consultants in IPC with both training and 
some	field	experience.
 § USAID in Indonesia developed a self-assessment 
tool for PMDT sites which includes IPC. The tool has 
been used in 10 PMDT sites and will be expanded 
to PMDT sites nationwide.
 § CDC provided extensive training of healthcare 
workers in AIC measures in India and China. CDC 
also supported facility assessments and oversaw 
facility renovations for developing and supporting 
model programs at apex institutes in India, NITRD 
(New Delhi) and Sewri TB Hospital (Mumbai). 
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Year Three Milestones Progress towards Years Three to Five Milestones
Develop guidance on evidence-
based best practices for 
TB infection control within 
healthcare facilities based 
on evidence-based policy 
recommendations.
 § USAID	supported	the	development	of	a	maintenance	manual	for	germicidal	ultraviolet	fixtures	and	
upper-room germicidal ultraviolet (GUV) air disinfection systems for TB transmission control. Based 
on lessons learned from South Africa and India, the guidelines implementation will be expanded in 
additional National Action Plan countries.
 § Through the WHO, USAID is supporting the update of the global TB IC guidelines
 § CDC designed an intervention package and toolkit to identify and address TB infection control gaps, 
implement routine monitoring and evaluation, and ensure continuous program improvement, TB 
BASICS in healthcare facilities.
 § In Nigeria, CDC and USAID provided support to improve infection control practices, including 
incorporating TB BASICS into national guidelines and curricula for healthcare workers, which is being 
scaled-up nationwide. 
 § In Mumbai, India, CDC is supporting the establishment of a novel AIC unit to assess, implement and 
evaluate infection control interventions in healthcare facilities treating TB using the TB BASICS tool. 
USAID and CDC will work in 
up to 10 countries to improve 
the implementation of infection 
control practices in facilities 
responsible for diagnosis and 
treatment of individuals with, and 
at high risk for, MDR-TB.
 § As of December 2017, seven countries have strengthened their IC practices for sites and facilities 
involved in management of DR-TB patients: India, Indonesia, Kazakhstan, Nigeria, Pakistan, South Africa 
and Ukraine.
 § In 2018, USAID will continue to work with the pilot countries to scale up activities initiated in 2017 
and engage the additional National Action Plan countries. 
 § USAID continues to work with countries to implement evidence-based practices for TB infection 
control in National Action Plan countries. In addition, to further implementation of the GUV guidelines, 
USAID will continue to expand the implementation of the FAST strategy, provide highly specialized 
training for IC consultants, build national IC capacities through support for Centers of Excellence (to 
include IC) and support innovative approaches to improved disease transmission measurements.
 § CDC is working with NCTB in China to implement TB BASICS in six counties (nine TB-designated 
health facilities) to improve infection control practices and to understand the feasibility and 
acceptability of TB BASICS in China. Training-of-trainers was conducted for the provincial China CDC 
staff.
USAID and CDC will work 
in up to 10 priority countries 
to introduce and/or improve 
healthcare worker surveillance 
and screening in facilities 
responsible for diagnosis and 
treatment of individuals with, and 
at high risk for, MDR-TB.
 § With USAID support, as of December 2017, eight National Action Plan countries have initiated activities 
focused on screening of healthcare workers. 
 § In South Africa, USAID supported the development of TB screening modules for healthcare workers 
(HCWs) including implementation of relatively new infection diagnostics such as Interferon-Gamma 
Release Assays (IGRAs).
 § In most of the National Action Plan countries, there are surveillance systems in place to capture incidence 
of TB among HCWs. Due largely to prevailing stigma, however, these data remain at sub-national level and 
often do not get reported to national authorities. 
 § The	number	of	HCWs	diagnosed	with	TB,	however,	is	increasing,	reflecting	the	improved	efforts	in	these	
countries on screening and detecting cases.
 § CDC is working with Mumbai Municipal Corporation of Greater Mumbai to establish a health-screening 
program for healthcare workers in Mumbai. HCWs will be screened for TB, hypertension and diabetes 
annually	by	the	AIC	unit	of	the	city	and	quarterly	by	the	medical	officer	of	the	respective	health	institution.	
The model will be scaled-up across the city and shared with the national program as a best practice for 
national scale-up. 
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GOAL 3
Objective: 3.1: Increase options for preventing active TB, latent TB infection, and TB transmission
Sub-objective 3.1.1. Advance research and development of novel vaccines
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
NIH will expand its dialogue 
among basic scientists, funders, 
and vaccine developers to 
identify novel strategies for 
vaccine development, encourage 
research related to vaccine 
design, and educate partners 
about resources available 
to contribute to vaccine 
development.
 § NIH: Workshop on March 7/8, 2016 on “The 
Impact of Mycobacterial Immune Evasion 
on Protective Immunity: Implications for TB 
Vaccine Design.”
 § NIH: Poster presentation on clinical resources 
for TB at the June 21/23, 2016 TB Summit in 
London, and on preclinical R&D resources 
at the EMBO Conference on Tuberculosis in 
September 2016 in Paris.
 § NIH: Established the Intramural TB 
Research Initiative (NITBRI) and held kick-
off symposium on June 27, 2016 “New 
Approaches to Combating Tuberculosis. 
Leveraging NIH Intramural TB Research for 
the Global Effort.”
 § NIH: Participated in the 2nd “Collaboration 
for TB Vaccine Discovery” (CTVD) meeting 
in July 2016, hosted by the Bill and Melinda 
Gates Foundation in Seattle, WA
 § NIH: Workshop on September 28/29, 2016 
on “Developing Functional Assays for TB 
Vaccine R&D: An Aeras/NIAID Workshop.”
 § NIH: Ongoing participation in R&D 
discussions/leverages resources with TB 
vaccine development product development 
partnerships	and	for	profit	organization.
 § NIH: Annual Meeting of the NIAID supported 
Vaccine Adjuvant Discovery Contract in 
November 2017. Novel adjuvants with potential 
utility in TB vaccines are being evaluated.
 § NIH: Participated in the 3rd annual “Collaboration 
for TB Vaccine Discovery” (CTVD) meeting in 
July 2017, hosted by the Bill and Melinda Gates 
Foundation in Seattle, WA. 
 § NIH: Workshop in September 2017 on “Molecular 
Mechanisms and Immune Consequences of 
Pathogen Reservoirs: Battling unseen enemies” in 
Rockville, MD.
 § NIH: Ongoing participation in R&D discussions 
with product development partnerships and 
for-profit	organization	to	assure	NIAID	resources	
are appropriately leveraged for TB vaccine 
development. 
 § NIH: Workshop in June 2017 on “Halting TB 
Transmission in HIV Endemic Settings”, in Cape 
Town, South Africa. Co-organized with the South 
Africa Medical Research Council (SAMRC), and 
the Bill & Melinda Gates Foundation (BMGF). 
 § NIH: Workshop in September 2017 on “TB 
Infection: Building a Framework for Eradication” in 
Dubai, United Arab Emirates. Co-organized with 
the Harvard Medical School Center for Global 
Health Delivery formulations.
 § NIH: Poster presentation on preclinical and clinical 
resources for TB at the January 2017 Keystone 
Symposia in Canada and the April 2017 ASM TB 
Conference in New York.
NIH will continue to support 
studies to map the diversity of 
immune responses required for 
vaccine	efficacy.
 § NIH: TB Research Portfolio (https://report.nih.
gov/categorical_spending.aspx)
 § NIH: Recent funding opportunities:
 § PAR-15-360: Characterization of 
Mycobacterial Induced Immunity in HIV-
infected and Uninfected Individuals (R21)
 § PAR-16-254: Mechanisms of Mycobacterial-
Induced Immunity in HIV-Infected and 
Uninfected Individuals to Inform Innovative 
Tuberculosis Vaccine Design (R01)
 § RFA-AI-16-079: Partnerships for 
Development of Vaccines to Prevent 
Mycobacterium tuberculosis Infection and/
or Tuberculosis Disease (R01)
 § RFA-AI-16-047: Partnerships for Structure-
Based Design of Novel Immunogens for 
Vaccine Development (R01) RFA-AI-16-034: 
Partnerships for Countermeasures Against 
Select Pathogens (R01)
 § NIH: TB Research Portfolio can be accessed here: 
https://report.nih.gov/categorical_spending.aspx
 § NIH: RFA-AI-17-039: Understanding Immuno-
pathogenesis of Tuberculosis in HIV-1 Infected and 
Exposed Children (R01 Clinical Trial Not Allowed)
 § NIH: PAR-15-360: Characterization of 
Mycobacterial Induced Immunity in HIV-infected 
and Uninfected Individuals (R21). Two awards 
were made in 2017. Progress from awards made 
in 2016 includes safety evaluation of an attenuated 
combination Mycobacterium tuberculosis vaccine 
strain that also co-expresses SIV antigens in 
SIV infected non-human primates; The vaccine 
is immunogenic but appears to facilitate oral 
SIV infection in infant macaques. (Clin Vaccine 
Immunol. 2017 Jan 5;24(1). pii: e00360-16. doi: 
10.1128/CVI.00360-16. Print 2017 Jan.) 
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 § NIH: Clinical Challenge Model for 
Assessment of Human TB Immunity 
(https://clinicaltrials.gov/ct2/show/
NCT01868464 )
 § NIH: PAR-16-254: Mechanisms of Mycobacterial-
Induced Immunity in HIV-Infected and Uninfected 
Individuals to Inform Innovative Tuberculosis 
Vaccine Design (R01). Five awards were made in 
2017.
Years Three to Five 
Milestones
Progress towards Years Three to Five Milestones
NIH will continue to support 
research, pre-clinical studies, 
and clinical trials and studies for 
the evaluation of new vaccines, 
adjuvants, and preventive drugs. 
 § NIH: Continues to support the development of a thermostable preparation of the Infectious Disease 
Research Institute (IDRI) ID93 GLA-SE TB vaccine under contract HHS N272201400041C.
 § NIH: 4 awards were made in response to RFA-AI-16-079: Partnerships for Development of Vaccines 
to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis Disease (R01).
 § NIH: Awarded Co-funding for the Phase 1/IIa Trial: MTBVAC Study in Adults with and without Latent 
Tuberculosis Infection in South Africa (A-050, NCT02933281) under grant 1U01AI131861.
 § NIH: Received Council approval for a 2019 grant initiative on “Halting TB Transmission in HIV Endemic 
Settings” (https://www.niaid.nih.gov/grants-contracts/june-2017-daids-council-approved-concepts).
 § NIH: Received Council approval for a 2018 contract initiative on “Immune Mechanisms of Protection 
Against Mycobacterium tuberculosis Center (IMPAc-TB) https://www.niaid.nih.gov/grants-contracts/
september-2017-dait-council-approved-concepts#04 
NIH and CDC will intensify 
collaborations with domestic and 
international vaccine developers 
to leverage pre-clinical and 
clinical resources for vaccine 
development. 
 § NIH: Continues to make its vaccine evaluation services available to vaccine developers and the 
academic community and will continue to support preclinical and clinical vaccine evaluations through 
its various clinical networks and targeted funding opportunities.
USAID will support platforms 
for TB vaccine researchers and 
key stakeholders in countries 
to facilitate collaboration and 
increase knowledge on TB 
vaccine research. 
USAID: Planning to support participation of researchers from selected countries at the 5th Global Forum 
on TB Vaccines on February 20-23, 2018, in New Delhi, India. This Forum is the world’s largest gathering 
of stakeholders striving to develop new vaccines to prevent TB. It provides a unique opportunity to 
review	the	state	of	the	field,	share	the	latest	research	and	findings,	and	identify	new	and	innovative	
approaches to TB vaccine R&D, with the end goal of developing and deploying new TB vaccines as 
quickly as possible. 
Department of State and the 
Department of Defense will 
explore a proof-of-concept 
randomized controlled study to 
assess whether BCG can provide 
short term protection to adults 
for prevention of TB infection 
during extended travel to high-
risk countries (for example, U.S. 
active military personnel and U.S. 
diplomatic corps); the published 
risk of infection is 4–8 percent 
for such travelers.
Sub-objective: 3.1.2. Support the development of methodologies to prevent transmission and development of TB and MDR-
TB
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID will initiate at least one 
study to evaluate the impact 
and cost-effectiveness of at least 
one TB prevention measure on 
TB and MDR-TB transmission 
in different care settings in high-
burden TB countries.
 § USAID: Weekly High dose Isoniazid and 
Rifapentine  Periodic Prophylaxis for TB 
(WHIP3TB) https://www.clinicaltrials.gov/ct2/
show/NCT02980016).
 § Other U.S. Government supported ongoing 
or planned clinical trials/studies 
 § NIH: Protecting Households On Exposure 
to Newly Diagnosed Index Multidrug-
Resistant Tuberculosis Patients (PHOENIx) 
(http://www.impaactnetwork.org/studies/
IMPAACT2003B.asp)
 § USAID: Weekly High-dose Isoniazid and 
Rifapentine  Periodic Prophylaxis for TB 
(WHIP3TB). Eight study sites (South Africa (RSA): 
5; Ethiopia: 2; Mozambique 1) are involved and 
have completed targeted enrollment (n=4000). 
90% of participants attended their 3-month follow-
up	visit,	no	safety	issues	identified.	Patient	centered	
practices are being implemented to maintain 
volunteer retention. Participants in the Periodic 
Prophylaxis (p3HP) arm will be offered another 
round of 3 months of Isoniazid + Rifapentine 
(3HP) in 2018 and 2019. https://www.clinicaltrials.
gov/ct2/show/NCT02980016).
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 § CDC/PEPFAR: Evaluation of an Enhanced 
Tuberculosis Infection Control Intervention in 
Healthcare Facilities in Vietnam and Thailand 
(EnTIC) (www.clinicaltrials.gov/ct2/show/
NCT02073240)
 § NIH: Evaluating the Pharmacokinetics, 
Tolerability, and Safety of Once-Weekly 
Rifapentine and Isoniazid in HIV-1-Infected 
and HIV-1-Uninfected Pregnant and 
Postpartum Women with Latent Tuberculosis 
Infection (www.clinicaltrials.gov/ct2/show/
NCT02651259)
 § NIH: Finding and Treating Unsuspected and 
Resistant TB to Reduce Hospital Transmission 
(R01-AI112748)
 § NIH: Cell Phone Video Directly Observed 
Therapy to Monitor Short Course LTBI 
Treatment (https://www.clinicaltrials.gov/ct2/
show/NCT02641106)
 § NIH: Innovative Interdisciplinary Approaches 
to Sustainable Airborne Infection Control 
(D43-TW9379)
 § NIH: Impact of Effective Chemotherapy on 
Transmission of Drug Resistant Tuberculosis 
(R01-AI099603)
 § CDC/USAID/PEPFAR: Evaluation of an Enhanced 
Tuberculosis Infection Control Intervention in 
Healthcare Facilities in Vietnam and Thailand 
(EnTIC) (www.clinicaltrials.gov/ct2/show/
NCT02073240). The study has been completed 
and data are expected in 2018. 
 § NIH: Protecting Households on Exposure to 
Newly Diagnosed Index Multidrug-Resistant 
Tuberculosis Patients (PHOENIx). Enrollment 
expected to begin 2Q2018. CDC is participating 
in protocol development, leading regional trainings, 
and providing technical assistance to the Philippines 
site.
 § NIH: The Phase I/II trial “Evaluating the 
Pharmacokinetics, Tolerability, and Safety of Once-
Weekly Rifapentine and Isoniazid in HIV-1-Infected 
and HIV-1-Uninfected Pregnant and Postpartum 
Women with Latent Tuberculosis Infection” 
continues enrollment. (www.clinicaltrials.gov/ct2/
show/NCT02651259).
 § NIH: Expecting results in 1Q2018 from the Phase 
III Clinical Trial of Ultra-Short-Course (one month) 
Rifapentine/Isoniazid for the Prevention of Active 
Tuberculosis in HIV-Infected Individuals with Latent 
Tuberculosis Infection www.clinicaltrials.gov/ct2/
show/NCT01404312).
 § NIH: Development and Clinical Evaluation 
of a Lyophilized, Thermostable Tuberculosis 
Vaccine (HHSN272201400041C).
 § DoD: Planning a randomized clinical trial of 
proof-of-concept of BCG immunization to 
prevent MTB infection in healthy adults.
 § NIH: Cell Phone Video Directly Observed Therapy 
to Monitor Short Course LTBI Treatment (https://
www.clinicaltrials.gov/ct2/show/NCT02641106) 
continues enrollment. 
 § CDC: Piloting with the Municipal Corporation 
of Greater Mumbai an innovative approach to 
TB prevention by establishing a local, city-wide 
air-borne infection (AIC) control unit to assess 
health facilities for infection control practices 
and implement AIC interventions to prevent 
transmission of MDR TB in Mumbai.
Years Three to Five 
Milestones
Progress towards Years Three to Five Milestones
USAID will evaluate at least 
one intervention to prevent 
the spread of MDR-TB based 
on assessments of probable 
transmission routes.
 § USAID: Planning several collaborative projects to characterize transmission of MDR-TB: Kyrgyzstan:- 
Study of nosocomial and community transmission of MDR-TB through combined analysis of whole 
genome sequencing data with spatial, epidemiological, demographic and laboratory information 
to understand the relative contribution of hospital acquired and transmitted resistance to the 
MDR-TB	epidemic	in	the	country;	and	contribute	to	active	case	finding	and	outbreak	surveillance	
for community transmission. The ultimate goal is to create data regarding community based and 
nosocomial TB transmission to guide effective risk management of TB and MDR-TB, and to strengthen 
and monitor infection control measures in hospitals. Moldova: Characterize TB transmission and 
identify and evaluate strategic new interventions for its reduction that could also be of value to global 
TB programs. The study will combine whole genome sequence analysis with spatial, epidemiological 
and laboratory information to: 1) characterize existing TB transmission patterns; 2) estimate the 
impact of TB interventions; and 3) better understand the relative contribution of acquired and 
transmitted resistance to the MDR TB epidemic in Moldova.
USAID and CDC will evaluate 
at least one new TB treatment 
regimen to prevent TB and 
MDR-TB in adults and children. 
 § USAID: Weekly High-dose Isoniazid and Rifapentine  Periodic Prophylaxis for TB (WHIP3TB) https://
www.clinicaltrials.gov/ct2/show/NCT02980016)
 § Will continue to evaluate two approaches to treatment of latent TB infection [3HP and periodic 
(p3HP) prevention treatment regimens in HIV co-infected individuals (adults and children)].
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Objective: 3.2: Improve the diagnosis of drug-resistant and drug-susceptible latent and active TB
Sub-objective: 3.2.1. Support the development of new tools and approaches for detection of drug-resistant TB
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
NIH will continue to support 
large-scale sequencing efforts to 
map the global genetic diversity 
of drug resistance in Mtb to 
define	genetic	markers	that	can	
be included in diagnostic tests 
to	improve	the	identification	of	
MDR-TB and XDR-TB.
 § NIH: TB portal at “Pathosystems Resource 
Integration System” (PATRIC) (https://www.
legacy.patricbrc.org/portal/portal/patric/TB) 
 § NIH: Center of Excellence for Translational 
Research – Integrated discovery and 
development of innovative TB Diagnostics 
(U19-AI109755)
 § NIH: The Mycobacterium tuberculosis portal at 
PATRIC is established as a public resource for 
researchers https://www.patricbrc.org/view/
Taxonomy/1773. PATRIC currently hosts more 
than 9300 Mycobacterium tuberculosis genomes 
and associated metadata that are consistently 
annotated to support comparative genomic 
analysis. Annotation services also include prediction 
of microbial resistance phenotypes which can 
aid in the design of novel diagnostics to identify 
MDR- and XDR-TB (NCBI GenBank Bioproject 
Accession number PRJNA343736). PATRIC 
also hosts data from the Omics4TB Disease 
Progression Program (www.omics4tb.org/, 
U19AI106761).
 § NIH: Continue support of a large-scale 
international Mycobacterium tuberculosis genome 
sequencing project at the Broad Institute Genomic 
Center for Infectious Diseases (U19AI110818). 
To date, the project has sequenced genomes of 
approximately 2,900 strains from South Africa, 
Uganda, Korea, Belarus, Moldova, Taiwan, Mali, India, 
Iran, Sweden, Romania, Peru, Thailand, Democratic 
Republic of Congo, Tanzania, Côte d’Ivoire, Georgia, 
and Azerbaijan, which includes contribution by the 
NIH supported IdEA consortium (https://www.
iedea.org/, to understand genetic diversity and 
patterns of drug resistance. Genomic data and 
associated metadata are publicly available (See 
PATRIC).
 § NIH: The TB Portals Program (https://tbportals.
niaid.nih.gov) is a web-based, open-access 
repository of socioeconomic/geographic, clinical, 
laboratory, radiological and genomic data from 
drug-resistant TB patient cases to facilitate multi-
national collaboration for data sharing and analysis. 
 § NIH: Genomic analysis of globally diverse 
Mycobacterium tuberculosis strains provides 
insights into the emergence and spread of 
multidrug resistance (Nature Genetics, http://www.
nature.com/articles/ng.3767).
NIH will continue to support 
non-clinical and clinical studies to 
evaluate early-stage diagnostic 
tests and will educate partners 
about resources available 
to contribute to diagnostic 
development.
 § NIH: RFA-AI-16-034: Partnerships for 
Countermeasures Against Select Pathogens 
(R01) 
 § NIH: Supported a prospective multicenter 
diagnostic accuracy study of the GeneXpert 
MTB/RIF Ultra for detection of Mycobacterium 
tuberculosis and rifampicin resistance 
(HHSN2722000900050C and K24AI104830) 
www.sciencedirect.com/science/article/pii/
S1473309917306916.
 § NIH: Supported a prospective diagnostic 
accuracy for an experimental new Xpert 
(Cepheid) cartridge for detection of resistance to 
Isoniazid,	fluoroquinolones	and	aminoglycosides	
(HHSN2722000900050C, https://clinicaltrials.gov/
ct2/show/NCT02251327) www.nejm.org/doi/
full/10.1056/NEJMoa1614915.
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 § NIH: Centers of Excellence in Translational 
Research (CETR) grant U19 AI109755 is 
developing sensitive diagnostic tests that are 
using minimally invasive and low volume samples 
to detect TB and drug resistance in adults and 
children. (JCM Accepted Manuscript Posted Online 
5 January 2018 J. Clin. Microbiol. doi:10.1128/
JCM.01652-17).	A	low	cost,	lateral	flow	cell	is	also	
being evaluated which has the potential to be used 
at the point of care. 
 § NIH: RFA-AI-17-042: Centers of Excellence for 
Translational Research (CETR) (U19 Clinical Trial 
Not Allowed)
USAID will initiate an evaluation 
of at least one promising 
(preferably point-of-care) TB and 
MDR-TB diagnostic tool in adults 
and children.
 § USAID: Planning an evaluation of the Cepheid 
“OMNI” point of contact diagnostic platform 
in low resource settings.
 § USAID: Evaluation of the Cepheid “OMNI” point 
of contact diagnostic platform in low resource 
settings is delayed pending release of the 
GeneXpert OMNI system by the manufacturing 
company (Cepheid). 
CDC will initiate baseline 
assessments of the entire 
diagnostic and treatment cascade 
for MDR-TB to identify factors 
that	affect	the	time	between	first	
patient contact, diagnosis, and 
treatment initiation.
 § CDC: Led an assessment of diagnostic 
and treatment cascade for MDR-TB in 
Mumbai to identify factors affecting time 
between	first	patient	contact,	diagnosis	and	
treatment initiation. CDC in collaboration 
with the Government of India has initiated 
interventions to address barriers to diagnosis 
and improve treatment initiation and 
adherence.
 § CDC: Collaborative demonstration project with 
the national and local TB program, as well as with 
private providers in Mumbai, India. This project is 
to develop a multi-pronged approach to address 
barriers to diagnosis and treatment of MDR-TB, 
provide	adherence	counseling	and	assure	efficient	
communication between public and private TB 
care providers to help identify TB patients. 
 § CDC: Supported early adoption of national 
guidelines for universal culture and drug 
susceptibility testing to fast track the diagnosis 
of	drug	resistance	and	modification	of	MDR-
TB treatment based on the resistance patterns, 
thus ensuring appropriate and effective MDR-TB 
treatment. Early results demonstrate improved 
retention and potentially improved treatment 
outcomes.
Year Three Milestones Progress towards Years Three to Five Milestones
USAID will complete evaluation 
of at least one promising 
(preferably a point-of-care) TB 
and MDR-TB diagnostic tool 
in adults and children with and 
without HIV. 
 § USAID: Evaluation of the Cepheid “OMNI” point of contact diagnostic platform in low resource 
settings is delayed pending release of the GeneXpert OMNI system by the manufacturing company 
(Cepheid). 
NIH will expand collaborations 
across the U.S. Government and 
with researchers and product 
developers to facilitate the 
integration of bacterial and 
host markers into diagnostic 
platforms.
 § NIH: Continues to develop funding opportunities and support structures to facilitate the development 
and feasibility evaluation of the most promising diagnostic candidates. See also ongoing studies listed 
under Additional Progress made during Year Two.
NIH will encourage and support 
evaluations of tests suitable for 
use in young children where 
diagnosis	of	TB	is	more	difficult.	
 § NIH: Continues to encourage research on predictive genomic and biological markers facilitating 
diagnosis of TB in children and their integration into suitable platforms. See also ongoing studies listed 
under Progress Made in Year Two.
CDC will pilot and evaluate a 
training program for measurable 
continuous quality improvement 
across the entire MDR-TB 
diagnostic cascade to shorten 
time to treatment initiation. 
 § CDC: Continues to support continuous quality improvement of Xpert testing in India by transferring 
and	piloting	an	agency-developed	proficiency	testing	program	to	TB	centers	to	help	assure	
presumptive RR/ MDR-TB patients receive accurate, reliable and timely diagnostic test results for 
early	and	appropriate	TB	treatment.	Scale	up	of	the	proficiency	testing	program	is	supported	in	
collaboration with the government of India and CDC partner stakeholders. 
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Sub-objective: 3.2.2. Support research to identify biological markers to help detect latent TB and progression to active TB in 
children and adults
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
NIH will continue to support 
biomedical research studies to 
identify novel biological markers 
and signatures to detect the 
likelihood of progression from 
infection to active TB.
 § NIH: A blood RNA signature for tuberculosis 
disease risk: a prospective cohort study 
(Lancet, http://dx.doi.org/10.1016/S0140-
6736(15)01316-1) 
 § NIH: Genome-wide expression for diagnosis 
of pulmonary tuberculosis: a multicohort 
analysis (Lancet Respir Med, http://www.
sciencedirect.com/science/article/pii/
S2213260016000485)
 § NIH:	PET	CT	Identifies	Reactivation	Risk	
in Cynomolgus Macaques with Latent M. 
tuberculosis (PLoS Pathogen, http://journals.
plos.org/plospathogens/article?id=10.1371/
journal.ppat.1005739)
 § NIH: Grant R01 AI128765 is focused on validation 
of potential serum and plasma-based diagnostic 
biomarker signatures of pediatric TB for further 
use	in	diagnosis	utilizing	five	well-defined	and	
volunteer independent cohorts.
 § NIH:	Grant	U01AI115940,	“Inflammatory	
determinants of disease severity and treatment 
outcome in TB patients” continues to deliver 
insights into biological markers that may be 
indicative of a person’s risk to develop active TB 
from latent Mycobacterium tuberculosis infection. 
 § Frontiers in immunology. 2017;8:968 (https://www.
frontiersin.org/articles/10.3389/fimmu.2017.00968/
full) 
 § Frontiers in immunology. 2017;8:542. https://www.
frontiersin.org/articles/10.3389/fimmu.2017.00542/
full 
 § Journal of immunology 2017:199(7):2440. http://
www.jimmunol.org/content/199/7/2440
NIH, CDC, and USAID will 
expand clinical cohorts in TB 
endemic countries to study 
correlates of progression from 
TB infection to active disease.
 § NIH: TBRU-N (https://www.niaid.nih.gov/
research/tuberculosis-research-units-network). 
The CDC-supported Kenya Medical Research 
Institute (KEMRI) in Kisumu is a clinical site for 
a Tuberculosis Research Unit that is enrolling 
a clinical cohort to identify immune markers 
that predict progression from latent TB 
infection to active disease.
 § NIH: RePORT network (http://reportcohort.
org/)
 § CDC: The TB Trials Consortium, in 
collaboration with NIH, is contributing 
specimens to a collaborative repository 
(CTB2 http://www.tbbiorepository.org/about-
ctb2) to contribute to the search for markers 
of progression from latent TB infection to 
active TB disease and to monitor treatment 
response.
 § NIH: RePORT network (http://reportcohort.
org/) has expanded to include cohorts in India, 
Brazil, South Africa, China, Indonesia and the 
Philippines and are continuing their studies to 
identify correlates of risk and progression of 
latent infection to active disease. Common 
protocols for sample and data collection are being 
implemented in all countries. The RePORT cohorts 
collaborated in the following recent grant awards: 
R01AI123310-
 § “IFN-y independent inhibition of MTB growth in 
human macrophages”; R21AI134129 
 § “The role of innate immunity in the acquisition of 
sterile protection against TB infection”. 
 § NIH: Continues to contribute TB samples through 
its AIDS Clinical Trials Consortium (ACTG) to 
the collaborative CTB2 consortium (http://www.
tbbiorepository.org/about-ctb2).
Year Three Milestones Progress towards Years Three to Five Milestones
NIH and CDC will support 
clinical studies to validate biologic 
correlates of disease activation. 
 § NIH:	Continues	to	encourage	and	support	identification	of	predictive	and	genomic	biological	markers	
in relevant epidemiological studies and facilitate evaluation of these markers for their suitability as 
prognostic tests. See also ongoing studies listed under Additional Progress Made in Year Two.
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Objective 3.3: Improve treatment options for drug-susceptible and drug-resistant TB
Sub-objective 3.3.1. Improve the use of existing TB drugs for treatment of drug-susceptible and drug-resistant TB
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
NIH will discuss innovative 
and pharmacologically-based 
strategies for the development 
of new, shorter regimens with 
the research and product 
development community and 
will educate partners about 
resources available to contribute 
to drug development.
 § NIH: Co-hosted two workshops on 
“Optimization of Oxazolidinones for Use 
in TB Drug Regimens” with the Stop TB 
Partnership’s Working Group on New Drugs 
(http://www.newtbdrugs.org/) in July and 
December 2016. 
 § NIH: Poster presentation on clinical resources 
for TB at the June 21/23, 2016 TB Summit in 
London, and on preclinical R&D resources 
at the EMBO Conference on Tuberculosis in 
September 2016 in Paris. 
 § NIH: Intramural TB Research Initiative 
(NITBRI) held kick-off symposium on June 
27, 2016, “New Approaches to Combating 
Tuberculosis. Leveraging NIH Intramural TB 
Research for the Global Effort.” 
 § NIH: provided preclinical resources to the 
Lilly TB Drug Discovery Initiative to study the 
antiparasitic drug Nitazoxanide for use against 
MTB.
 § NIH: Poster presentation describing NIH 
extramural preclinical resources for TB product 
development at the January 2017 Keystone 
Symposium on “New Developments in our 
Basic Understanding of Tuberculosis” (Vancouver, 
Canada), the April 2017 ASM Conference on 
“Tuberculosis: Past, Present and Future” (New 
York) and the June 2017 Gordon Conference on 
“New Approaches, New Chemical Entities and 
New Targets for Tuberculosis Drug” (Lucca, Italy).
 § NIH: Continues to provide preclinical resources 
to the Lilly TB Drug Discovery Initiative to help 
accelerate discovery and development of new 
drugs to treat TB. NIH supported early studies 
of CPZEN-45, an inhalable nucleoside antibiotic, 
that is now entering advanced development 
https://www.genengnews.com/gen-news-
highlights/idri-hisun-to-partner-in-developing-tb-
candidate-cpzen-45/81254853. Other chemical 
entities are emerging from this initiative that 
had been supported by NIAID (Oxaboroles, 
Imidazopyridines and Spectinamides). 
 § NIH: Co-hosted a workshop with the Critical Path 
to TB Regimens (CPTRinitiative.org) in September 
2017 on “Evolution of a data driven preclinical 
roadmap for novel TB regimens: Emphasis on 
animal models and pharmacometrics for selection 
of	efficient,	rational	sequential	TB	Treatment	
Regimens.” 
 § NIH: Workshop in September 2017 on “Molecular 
Mechanisms and Immune Consequences of 
Pathogen Reservoirs: Battling unseen enemies” – 
general workshop of interest to the TB community. 
 § NIH/FDA: Public Workshop in July 2017 
on	“Bacteriophage	Therapy:	Scientific	and	
Regulatory Issues” (https://www.fda.gov/
BiologicsBloodVaccines/NewsEvents/
WorkshopsMeetingsConferences/ucm544294.htm)
 § NIH/FDA: The NIH Intramural TB Research 
Initiative (NITBRI) and FDA co-hosted in April 
2017 a “World TB Day Mini-Symposium” in 
Washington, DC.
 § NIH: Continues to co-chair the StopTB 
Partnership’s Working Group on new Drugs 
(http://www.newtbdrugs.org/core-group) 
and presented the updated global TB drug 
development pipeline in July, 2017 at the annual 
meeting of the International Consortium for 
Trials of Chemotherapeutic Agents in Tuberculosis 
(INTERTB) in London, UK. 
 § NIH: The Vaccine Research Center (VRC, https://
www.niaid.nih.gov/about/vrc) continues studies into 
the effect of TB Therapy on immune responses 
against Mycobacterium tuberculosis. (https://www.
ncbi.nlm.nih.gov/pubmed/27367521).
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USAID will initiate an assessment 
of new methods or packages 
of care to enhance treatment 
success.
 § USAID: USAID has developed and will soon 
pilot an ancillary care package to identify key 
services and interventions needed to support 
MDR-TB patients through the diagnosis and 
treatment	processes.	During	the	first	year	
of the NAP, USAID undertook a survey of 
patients, providers and technical partners 
to identify the key barriers to successful 
MDR-TB diagnosis and treatment. The results 
of this survey were used to draft a simple 
tool that will allow providers to assess the 
needs	of	specific	patients	and	prioritize	
support	activities	that	best	fit	those	needs,	
with the ultimate aim of improving treatment 
outcomes. In Year Two, this tool will be piloted 
in four NAP countries.
 § USAID has been supporting the development and 
introduction of package of care that will contribute 
to the improvement in patient adherence to MDR-
TB treatment.
 § During the previous reporting period, USAID 
drafted a list of comprehensive ancillary services 
based on patient needs and a survey of the 
literature; developed a brief Practical Guide to 
Delivering Essential Supportive Care to Patients 
with Drug-resistant Tuberculosis and accompanying 
tools	to	ease	implementation;	and	identified	four	
pilot countries (China, Pakistan, South Africa, 
and Ukraine) in which to test the approach and 
materials and evaluate results. The pilot efforts 
will	inform	further	refinement	of	the	package	
of patient services and the guidance documents 
with the goal of scaling up the approach in 2018, 
focusing on 10 high-priority countries.
 § Achievement: During this reporting period the 
four countries participating in the pilot project 
started implementing activities. China has already 
completed the enrollment with 240 patients in 
the intervention arm and 270 patients in control 
group.	China	is	expecting	to	finalize	data	analysis	
by May 2018. The South African pilot project has 
enrolled 85 patients and is on track for completing 
the enrollment by the end of December. Ukraine 
has so far enrolled 80 patients and is expect to 
complete	enrollment	during	the	first	quarter	of	
2018. Pakistan has started enrollment in October 
2017.
USAID and CDC will continue 
to support ongoing studies in 
adults to assess shorter MDR-TB 
regimens using existing TB drugs.
 § CDC, USAID: Provided technical assistance 
to initiate a clinical protocol assessing 
feasibility, effectiveness, and safety of the newly 
recommended 9-month treatment regimen 
for MDR-TB in the National TB Control 
Program of the Philippines. 
 § CDC: Leading a multi-site clinical trial to 
assess	the	bactericidal	activity	of	specific	
anti-TB drugs to guide treatment decisions 
when susceptibility test results differ between 
closely related drugs, which occurs in a large 
fraction of patients. This study should inform 
clinical and laboratory practice and guidelines 
and may expand options for treatment for 
certain patients. 
 § NIH:	Efficacy	and	Safety	of	Levofloxacin	
for the Treatment of MDR-TB (Opti-Q) 
(https://www.clinicaltrials.gov/ct2/show/
NCT01918397)
 § NIH: Trial of High-Dose Rifampin in Patients 
With TB (HIRIF) (https://www.clinicaltrials.gov/
ct2/show/NCT01408914)
 § CDC/USAID: Based on a 2015-2016 pilot study to 
assess the feasibility, effectiveness, and safety of the 
newly recommended 9-month treatment regimen 
for MDR-TB in the National TB Control Program 
of the Philippines, the National TB Control 
program is now implementing a national scale up 
plan to introduce the standard short treatment 
regimen (SSTR) for all qualifying patients.
 § USAID:	Contributed	to	Stage	1	of	the	first	
randomized	controlled	trial	to	test	the	efficacy,	
safety and economic impact of a standardized 
shorter MDR-TB regimen (STREAM). Preliminary 
data were made public in 2017 and suggest that 
efficacy	of	the	nine-month	regimen	will	be	closely	
related to the regimen recommended in the 2011 
WHO guidelines, which has a duration of 20–24 
months. (www.theunion.org/news-centre/news/
stream-clinical-trial-results-provide-vital-insight-
into-nine-month-treatment-regimen-for-multidrug-
resistant-tuberculosis). Final Stage 1 data are 
expected in 2018. 
 § NIH:	Phase	II	trial	on	the	“Efficacy	and	Safety	
of	Levofloxacin	for	the	Treatment	of	MDR-TB	
(Opti-Q)” (https://www.clinicaltrials.gov/ct2/show/
NCT01918397) has been completed and is in data 
analysis. 
 § NIH: Phase II Trial of “High-Dose Rifampin in 
Patients with TB (HIRIF)” (https://www.clinicaltrials.
gov/ct2/show/NCT01408914) has been 
completed. Data are being published (Antimicrob 
Agents Chemother. 2017 Jul 25;61(8). pii: e00038-
17. doi: 10.1128/AAC.00038-17. Print 2017 Aug.)
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Year Three Milestones Progress towards Years Three to Five Milestones
USAID will evaluate pilots of 
innovative strategies to improve 
treatment outcomes in at least 
five	countries.	
 § USAID: All countries implementing pilot studies to contribute evidence to the MDR-TB Package 
of	Care	(South	Africa,	Ukraine,	Pakistan,	and	China)	are	expected	to	finish	patient	enrollment,	data	
analysis	and	dissemination	of	findings	in	2018	to	all	ten	countries	included	in	the	National Action Plan. 
Findings from these pilot studies will inform implementation of the Package of Care in the remaining 
six countries. 
NIH will support research to 
improve knowledge about the 
pharmacology	of	first-	and	
second-line TB drugs in various 
patient populations to optimize 
therapy for the largest number 
of patients, including children. 
 § NIH: Supporting a Phase 1 trial to study the “Pharmacokinetics and safety of PA-824 in Subjects with 
mild, moderate and sever hepatic impairment compared with matched non-hepatically impaired 
subjects” (https://clinicaltrials.gov/ct2/show/NCT02422524). (Note: While PA-824 (Pretomanid) is 
not an approved drug, it is being studied as part of a new three-drug regimen in Phase III clinical 
trials with promising preliminary results (https://clinicaltrials.gov/ct2/show/NCT02333799, http://www.
croiconference.org/sessions/nix-tb-trial-pretomanid-bedaquiline-and-linezolid-treat-xdr-tb). )
NIH will contribute to the 
development of pediatric 
formulations for new and existing 
TB drugs. 
 § NIH: Accepting applications under the SBIR Phase II program to continue work on the development 
of pediatric formulations. Results from SBIR Phase I awardees have been made public: https://
globenewswire.com/news-release/2017/08/22/1091157/0/en/CURE-Pharmaceutical-Subsidiary-Oak-
Therapeutics-Completes-Critical-Milestone-in-Phase-1-of-NIH-Grant-to-Develop-Oral-Dissolvable-
Strip-for-Tuberculosis.html, http://lunainc.com/union-world-conference-lung-health/. 
 § NIH: Issued PAR-17-193: Development of Appropriate Pediatric Formulations and Pediatric Drug 
Delivery Systems (R01). 
Sub-objective 3.3.2. Enhance knowledge to enable optimal and safe use of newly registered TB drugs
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID will support the 
evaluation of new and shorter 
TB regimens containing novel 
anti-TB drugs in adults.
 § USAID: Co-sponsoring “A Phase 3 Study 
Assessing	the	Safety	and	Efficacy	of	
Bedaquiline Plus PA-824 Plus Linezolid in 
Subjects With Drug Resistant Pulmonary 
Tuberculosis (NiX-TB, https://clinicaltrials.gov/
ct2/show/NCT02333799)
 § USAID is developing a package of care to 
support treatment adherence for MDR-TB 
patients: Several meetings held with Key 
stakeholders to inform the content of the 
package of care that will be evaluated
Other U.S. Government supported ongoing or 
planned clinical trials/studies
 § NIH: A Trial of the Safety, Tolerability, and 
Pharmacokinetics of Bedaquiline and 
Delamanid, Alone and in Combination, among 
Participants Taking Multidrug Treatment for 
Drug-Resistant Pulmonary Tuberculosis. 
(https://clinicaltrials.gov/show/NCT02583048).
 § NIH: Evaluating the Pharmacokinetics, Safety, 
and Tolerability of Bedaquiline in HIV-Infected 
and HIV-Uninfected Infants, Children, and 
Adolescents With Multidrug-Resistant 
Tuberculosis (https://clinicaltrials.gov/ct2/show/
NCT02906007) 
 § NIH: Planning a clinical trial to evaluate 
the	Safety,	Tolerability,	and	Initial	Efficacy	of	
Linezolid Combined with Delamanid and 
Optimized Background Therapy (OBT) 
for the Treatment of Multidrug Resistant 
Tuberculosis.
 § USAID: Co-sponsored “Phase 3 Study Assessing 
the	Safety	and	Efficacy	of	Bedaquiline	Plus	
PA-824 Plus Linezolid in Subjects with Drug 
Resistant Pulmonary Tuberculosis (NiX-TB, https://
clinicaltrials.gov/ct2/show/NCT02333799) has 
ended	recruitment.	has	officially	ended	for	the	
Nix-TB trial. Preliminary results relapse-free cure 6 
months after completion of the 6-month therapy 
for	the	first	45	patients	with	XDR-TB	completing	
6-month treatment and 6-month follow-up for 
relapse. Current cure rates for XDR-TB patients 
on prolonged therapy are only 16 percent. 
 § USAID:	Contributing	to	Stage	2	of	the	first	
randomized	controlled	trial	to	test	the	efficacy,	
safety and economic impact of a standardized 
shorter MDR-TB regimen (STREAM, https://
clinicaltrials.gov/ct2/show/NCT02409290). This trial 
will recruit patients in 10 countries. 
 § NIH: The Phase I/II trial to “Evaluate the 
Pharmacokinetics, Safety, and Tolerability of 
Bedaquiline in HIV-Infected and HIV-Uninfected 
Infants, Children, and Adolescents with Multidrug-
Resistant Tuberculosis” is expected to begin 
enrollment in 2Q2018 (https://clinicaltrials.gov/ct2/
show/NCT02906007) 
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Years Three to Five 
Milestones
Progress towards Years Three to Five Milestones
NIH and CDC will support 
clinical trials to assess the 
safety and drug interactions of 
bedaquiline, delamanid, or both. 
 § See ongoing studies listed under Additional Progress Made in Year Two. 
NIH, CDC, and USAID will 
support clinical trials to 
evaluate clinical evidence for 
the integration of bedaquiline, 
delamanid, or both into 
currently approved regimens to 
inform new guidelines for the 
management of drug-resistant TB.
 § USAID:	Collaborating	with	the	TB	Alliance	on	a	Phase	2c	trial	to	Evaluate	the	Efficacy,	Safety	and	
Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult 
Patients (SimpliciTB, https://clinicaltrials.gov/ct2/show/NCT03338621). 
 § USAID:	Collaborating	with	the	TB	Alliance	on	a	Phase	III	trial	to	evaluate	the	Safety	and	Efficacy	of	
Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants 
with Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNiX, https://
clinicaltrials.gov/ct2/show/NCT03086486). 
 § USAID: Participating in the planning of a collaborative, public-private open label Phase 3 clinical trial 
to	evaluate	the	Efficacy	and	Safety	of	a	Combination	regimen	of	Bedaquiline,	Delamanid,	Linezolid	and	
Clofazimine	in	Multidrug	resistant	(MDR)	patients	with	additional	resistance	to	fluoroquinolones	and/
or aminoglycoside in South Africa and India (BEAT TB).
CDC and USAID will identify 
best practices for the use of 
new drugs in novel MDR-TB 
treatment regimens based on 
pharmacovigilance data. 
 § USAID: All clinical trials that include novel therapeutics also assess the safety for these drugs. 
Furthermore, technical support for all programs that are focused on the introduction of shortened 
regimens and new drugs (STR/ND) for treatment of MDR-TB prioritizes pharmacovigilance. The 
USAID-Johnson and Johnson Bedaquiline Donation Program also prioritizes pharmacovigilance and 
convened key stakeholders from Asia – Thailand, Burma, China, India, Indonesia, Pakistan, Papua New 
Guinea, Philippines, South Korea, Thailand and Vietnam for a Regional Pharmacovigilance Workshop 
from 25 to 27 April 2017 in Bangkok. Thailand. Two more Workshops have been planned for the 
Spring of 2018 to cover the African Region (to be convened in South Africa) and the Eastern 
Europe/Central Asia Regions (to be convened in Kazakhstan and). The intended outcomes of these 
workshops are drug safety monitoring and management (aDSM) roadmaps, that are developed by 
each country to guide planned and ongoing activities, establish and/or strengthen reporting structures 
and enhance coordination and partnership for the introduction and scale-up of ND and STR for 
MDR-TB patient care. The aDSM roadmap will be used to assess what technical assistant may be 
required by a country and to measure progress by the end of 2019. The key components of these 
aDSM road maps are adapted from the WHO aDSM framework and include i) national coordination 
and policy guidelines and implementation plan; ii) recording and reporting structures; iii) development 
of health care workers capacity; iv) clinical management; and v) data management and analysis. 
USAID and CDC will expand 
the evaluation of new drug 
regimens to treat children, 
including novel TB drugs for both 
TB and MDR-TB. 
 § CDC: The STEP-TB Project (Janssen, UNITAID/TB Alliance) is enrolling HIV-negative infants, children, 
and adolescents with MDR-TB (0-18 years old); children ≤12 years old (n=60) will receive pediatric 
formulations to characterize the pharmacology of Bedaquiline for four age groups: i) 0 months to < 2 
years; ii) > 2 to < 5 years; iii) < 5 to <12; and iv) <12 to <18 years) to aid in dose selection guidance 
for pediatric use. 
 § USAID: Under the STREAM trial, Janssen Pharmaceuticals is enrolling adolescents with MDR-TB.
Sub-objective 3.3.3. Develop novel drugs and shorter regimens to treat drug-resistant TB and improve the selection of drug 
candidates for clinical trials
Year One Milestones Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
NIH will support novel 
therapeutic approaches for the 
treatment of TB, such as host-
directed therapeutics (HDT). 
 § NIH: RFA-AI-16-034: Partnerships for 
Countermeasures Against Select Pathogens 
(R01)
 § NIH: Supporting 4 awards under the Initiative 
“Host Directed TB Therapy: New Approaches 
(UH2/UH3)
 § NIH: Preclinical TB drug discovery services 
are currently accessed by over 100 research 
groups annually in more than 30 countries. 
 § NIH intramural: Exploratory research 
in immune targeted adjuncts to TB 
chemotherapy. 
 § NIH: RFA-AI-16-034: Partnerships for 
Countermeasures Against Select Pathogens. One 
award was made in 2017 that will focus on new 
drug targets against TB (R01AI132300).
 § NIH: At the Gordon Research Conference on 
Tuberculosis Drug Discovery & Development in 
June 2017, presented a poster on “Host Directed 
Therapy for TB/HIV Co-Infection: Preclinical Studies 
and Early Clinical Plans at DAIDS” and a talk on 
“Preclinical Pathway to Host-Directed Therapy for 
TB/HIV Co-Infection” at a satellite workshop on 
“Strategic Discussion on Repurposing Drugs & 
Host Directed Therapies for TB”. 
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 § NIH intramural: Collaborating agency in the 
Bill and Melinda Gates Foundation’s Drug 
Accelerator Program. 
 § NIH: Optimizing Combination Therapy to 
Accelerate Clinical Cure of Tuberculosis (P01 
AI123036)
 § NIH: New chemical entities are entering 
preclinical studies through the NIH supported 
Lilly TB Drug Discovery Partnership (https://
www.niaid.nih.gov/research/partnership-eli-
lilly)
 § NIH: Hosted workshop on “Tuberculosis Meningitis: 
Advancing Immuno-pathogenesis, Diagnosis, and 
Treatment” in May 2017.
 § NIH: Two awards transitioned to the second phase 
of RFA-AI-14-058 “Host Directed TB Therapy: 
New Approaches (UH2/UH3)” to begin Phase II 
clinical trials in 2018. 
 § NIH: Issued PA-17-283 (R01) and PA-17-282 
(R21): “Therapeutic Strategies for the Converging 
TB/T2DM/HIV Epidemics”
 § NIH: Issued RFA-AI-17-101 (R61/R33): 
“Dysregulation of Immune Cell Regulatory 
Pathways by Mycobacterium tuberculosis in the 
Context of HIV Infection”
 § NIH: Continues to provide preclinical assays and 
animal model services to assist in the discovery of 
new chemical entities against TB. Approximately 
100 research groups in over 30 countries 
worldwide are being supported. 
 § NIH: Contributing to the preclinical development 
of a novel chemical entity for drug-resistant TB 
through the Lilly TB Drug Discovery Initiative. 
Safety	and	efficacy	studies	have	supported	
CPZEN-45’s candidacy, and the Infectious 
Disease Research Institute has completed 
a co-development agreement with Hisun 
Pharmaceuticals.
 § NIH intramural: Continues exploratory research 
in immune targeted adjuncts to TB chemotherapy 
and determined that pharmacologic inhibition of 
a newly discovered biochemical pathway inhibits 
growth of Mycobacterium tuberculosis in cells and in 
mice (manuscript in preparation). 
 § NIH intramural: Conducting an international 
trial “Using Biomarkers to Predict TB Treatment 
Duration” (https://clinicaltrials.gov/ct2/show/
NCT02821832) in collaboration with the Bill and 
Melinda Gates Foundation, the European and 
Developing Countries Clinical Trials Partnership, 
the National Natural Science Foundation of China, 
and the China Ministry of Science and Technology, 
and the NIH. 
 § NIH intramural: Collaborating agency in the Bill 
and Melinda Gates Foundation’s Drug Accelerator 
Program.
Years Three to Five 
Milestones
Progress towards Years Three to Five Milestones
NIH will expand and strengthen 
support for the pre-clinical 
evaluation of new drug 
candidates and regimens for the 
treatment of drug-susceptible 
and drug-resistant TB. 
 § NIH: Continues its preclinical services to facilitate early stage evaluations of drug candidates for 
academic organizations and product developers. See also ongoing studies listed under Additional 
Progress Made in Year Two.
NIH will increase collaborations 
with pharmaceutical and 
academic partners to broaden 
strategies for shortening 
treatment duration. 
 § NIH: Co-hosted a workshop with the Critical Path to TB Regimens (CPTRinitiative.org) in September 
2017 on “Evolution of a data driven preclinical roadmap for novel TB regimens: Emphasis on animal 
models	and	pharmacometrics	for	selection	of	efficient,	rational	sequential	TB	Treatment	Regimens”.	
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NIH will contribute to 
establishing state-of-the-science 
pre-clinical approaches and 
strategies for the selection of the 
most promising drug candidates 
and regimens for clinical trials. 
 § NIH: Researchers supported under U19-AI111143, Tri-Institutional TB Research Unit: Persistence 
and Latency developed a laboratory assay that detects viable but not culturable antibiotic tolerant 
Mycobacterium tuberculosis cells for eventual use as part of clinical trials ([http://www.pnas.org/
content/114/24/E4832.full.pdf) 
NIH, CDC, and USAID 
will increase inclusion of 
pharmacological evaluations in 
clinical and non-clinical studies 
to better understand the 
effectiveness of new drugs and 
regimens and to minimize side 
effects. 
 § USAID:	The	planned	collaborative	Phase	3	clinical	trial	to	evaluate	the	Efficacy	and	Safety	of	a	
Combination regimen of Bedaquiline, Delamanid, Linezolid and Clofazimine in Multidrug resistant 
(MDR)	patients	with	additional	resistance	to	fluoroquinolones	and/or	aminoglycoside	(BEAT	TB)	will	
include estimates of blood levels for all study drugs and their metabolites to help interpret safety and 
efficacy	findings.	
 § USAID:	The	collaborative	Phase	III	trial	to	evaluate	the	Safety	and	Efficacy	of	Various	Doses	and	
Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants with Pulmonary 
TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNiX, https://clinicaltrials.gov/
ct2/show/NCT03086486) intends to optimize the dosing and duration of linezolid that was used in 
the NiX-TB regimen (https://clinicaltrials.gov/ct2/show/NCT02333799). The ZeNIX trial will include 
pharmacokinetics of six different dosing schedules of Linezolid in patients with drug sensitive TB.
Objective 3.4: Increase capacity to conduct biomedical and clinical research on TB in TB-endemic countries
Years One to Three 
Milestones
Year One Achievements  
(previously reported)
Additional Progress Made in Year Two
USAID will create an inventory 
(map) of potential sites 
and initiate needs-based 
procurement of equipment to 
prepare study sites.
 § USAID has initiated discussion in South 
Africa to do identify new research sites for 
upcoming clinical trials for the treatment of 
MDR-TB.
 § USAID: In discussions with the South African 
Ministry of health, the Eastern Cape, which has 
many MDR and XDR-TB patients but very poor 
cure	rates,	has	been	identified	as	benefiting	
from strengthening research capabilities and 
collaborations. The BEAT TB clinical trial will 
therefore be initiated at the Eastern Cape 
provinces in South Africa to increase equity for 
access to clinical research within the country. 
NIH, CDC, and USAID will 
provide training in clinical 
research to high-burden TB 
countries with the capacity 
to conduct biomedical clinical 
research to facilitate their active 
participation in trials and studies.
 § CDC: Providing technical assistance to the 
Kenya Medical Research Institute (KEMRI) 
in Kisumu for oversight and conduct of 
therapeutic, preventative, diagnostic and 
implementation clinical trials for TB and TB/
HIV
 § NIH: Through the Fogarty International 
Center, targeted training programs for TB and 
HIV/TB	are	supported	under	five	framework	
programs in Global Research 
NIH Supported Funding Opportunities:
 § PAR-17-057 – Global Infectious Disease 
Research Training Program (D43)
 § PAR-16-279 - Fogarty HIV Research Training 
Program for Low-and Middle-Income 
Country Institutions (D43)
 § PAR-16-082 - International Bioethics Research 
Training Program (D43) 
 § PAR16-081 - International Research Ethics 
education and Curriculum Development 
Awards (R25)
 § RFA-AI-16-082/083 – Revision Applications 
for U.S. South Africa Program for 
Collaborative Biomedical Research (various 
funding mechanisms)
 § NIH: Funded one award under RFA-AI-16-082/083 
– “Revision Applications for U.S. South Africa 
Program for Collaborative Biomedical Research” 
(various funding mechanisms) 
 § NIH: PAR-17-057 – Global Infectious Disease 
Research Training Program (D43)
 § NIH: PAR-16-279 - Fogarty HIV Research Training 
Program for Low-and Middle-Income Country 
Institutions (D43)
 § NIH: PAR16-081 - International Research Ethics 
education and Curriculum Development Awards 
(R25)
 § NIH: PAR-17-057 - Global Infectious Disease 
Research Training Program (D43)
 § NIH: PAR-17-001- Emerging Global Leader Award 
(K43)
 § NIH: PAR-17-142 - International research in 
Infectious Diseases, Including AIDS (R01) 
 § NIH: PAR-17-474 – Reducing Stigma to Improve 
HIV/AIDS Prevention, Treatment and care in low 
and middle-Income Countries (R21) 
 § NIH: RFA-TW-17-001 – Health-Professional 
Education Partnership Initiative (HEPI) (R25 
Clinical Trial Not Allowed) 
 § NIH: RFA-TW-18-001 – African Association for 
Health Professions Education and Research (R25 
Clinical Trials Not Allowed) 
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 § PAR-14-193 - Fogarty Global Infectious 
Disease Research Training Program 
 § NIH: PAR-15-291 - International Research 
Scientist Development Award (IRSDA) (K01)
 § PAR-15-292: Emerging Global Leader Award 
(K43)
 § PAR-14-080 International research in 
Infectious Diseases, Including AIDS (IRIDA) 
(R01) 
 § NIH: Fogarty International Center held a 
“Tuberculosis Network Meeting” on June 
21, 2016, to expand their dialog among 
international trainees supported through their 
training centers
 § USAID: Supported capacity building for 
operational research (OR) through the “TREAT 
TB” mechanism. In the Philippines, 16 participants 
from the national TB program and key partner 
organizations	completed	the	first	training	module	
in May 2017. In Peru. 6 participants completed the 
OR course and prepared preliminary manuscripts 
for publication in peer-reviewed journals. Five 
abstracts were also accepted for presentation 
at the 48th Union World Conference on Lung 
Health. Course facilitators will continue to provide 
mentorship and guidance to course participants to 
finalize	and	publish	their	manuscripts.
 § CDC:	Hired	1.5	additional	FTE	(0.5	medical	office,	
1.0 administrative) to provide technical assistance 
for TB-related studies at KEMRI in Kisumu, 
Kenya. Provision of technical assistance has been 
hampered by political instability from national 
elections and resultant travel restrictions from July 
to December 2017.
NIH will expand opportunities 
for funding of biomedical 
clinical research in TB-endemic 
countries.
 § NIH: Expanding Regional, Observational 
TB Cohorts (RePORT Network – FHI 360 
website when available) in high-burden TB 
countries to facilitate collaborative, clinical 
research
 § NIH: H3 Africa Program (http://www.h3africa.
org/)
 § NIH: Continues to contribute to the expansion 
of the Regional, Observational TB Cohorts 
(RePORT Network) in high-burden TB countries 
to facilitate collaborative, clinical research (https://
www.reportinternational.org/. The 6th RePORT 
India leadership meeting was held Feb 2-4, 2017, 
in Hyderabad, India. The 3rd RePORT International 
Symposium was held Sept 12-13, 2017, in Rio de 
Janeiro, Brazil. RePORT investigators continue their 
independent, in country-focused research studies. 
Cross consortium studies are active in India, Brazil 
and South Africa to assess the impact of diabetes 
on TB and studying biomarkers in children and 
persons with HIV/M. tuberculosis co-infection. 
 § NIH: Phase II of the H3 Africa Program (http://
www.h3africa.org/ was published in 2016 (RFA-
RM-16-016, Human heredity and Health in Africa 
(H3 Africa): Collaborative Centers (U54)) and 
awards made in 2017. Under the Collaborative 
African Genomics Network (CAfGEN), NIH 
continues to support projects to study host 
response to HIV/TB in pediatric populations. 
 § NIH, CDC, USAID, Department of State: 
Attended	first	ministerial	conference	on	TB	in	
Russia, presented (NIH) plenary talk on the 
importance of research for global TB elimination 
(http://www.ajtmh.org/content/journals/10.4269/
ajtmh.17-0999). 

